阅读说明：本技术 具有hsp90抑制活性的新型化合物或其药学上可接受的盐及其医疗用途 (Novel compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof and medical use thereof ) 是由 徐荣晧 于 2017-01-31 设计创作，主要内容包括：本发明涉及具有HSP90抑制活性的新型化合物或其药学上可接受的盐及其医药用途,以及包含二羟基苯基化合物或苯甲酰胺化合物的组合物,其是本发明所述具有HSP90抑制活性的新型化合物,可有效抑制HSP90,因此可有效地用作对HSP90介导的疾病进行预防或治疗的药物组合物或用于对HSP90介导的疾病进行预防或改善的保健功能食品,上述疾病选自于由癌症疾病、退行性神经疾病和病毒感染所组成的组。(The present invention relates to a novel compound having HSP90 inhibitory activity or a pharmaceutically acceptable salt thereof and a medical use thereof, and a composition comprising a dihydroxyphenyl compound or a benzamide compound, which is the novel compound having HSP90 inhibitory activity of the present invention, can effectively inhibit HSP90 and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of HSP 90-mediated diseases selected from the group consisting of cancer diseases, degenerative neurological diseases and viral infections or a health functional food for the prevention or improvement of HSP 90-mediated diseases.)

1. A benzamide compound represented by the following chemical formula 2 or a pharmaceutically acceptable salt thereof:

[ chemical formula 2]

Wherein R is₁Is halogen or C1-C4 alkyl,

R₂is that

R₃And R₄May be the same as or different from each other, and is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy,

R₅and R₆May be the same or different from each other and is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy, or R₅And R₆Are connected with each other to form a five-membered ring or a six-membered ring,

R₇is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy,

R₈is a compound of the formula (I) or a halogen,

R₉is selected fromAny one of the group consisting of C1-C4 alkyl, C1-C4 alkoxy and benzyl.

2. The benzamide compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R is in the benzamide compound represented by chemical formula 2₁Is halogen or C1-C4 alkyl, R₂Is thatR₃Is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy, R₉Is any one selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, and benzyl.

3. The benzamide compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the benzamide compound represented by chemical formula 2 is any one selected from the group consisting of: n-benzyl-5-chloro-2, 4-dihydroxybenzamide, N-benzyl-5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N- (4-methoxybenzyl) -N-methylbenzamide, 5-chloro-N- (3, 4-dimethoxybenzyl) -2, 4-dihydroxy-N-methylbenzamide, N- (benzo [ d ] [1,3] dioxol-5-ylmethyl) -5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (3,4, 5-trimethoxybenzyl) benzamide, 5-chloro-N- (2-chloro-3, 4, 5-trimethoxybenzyl) -2, 4-dihydroxy-N-methylbenzamide, N- (2-bromo-3, 4, 5-trimethoxybenzyl) -5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (3-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (2-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4- (methylcarbamoyl) benzyl) benzamide, 5-chloro-N- (4- (ethylcarbamoyl) benzyl) -2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide, 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (methylcarbamoyl) benzyl) benzamide, N- (4- (ethylcarbamoyl) benzyl) -2, 4-dihydroxy-5-isopropyl-N-methylbenzamide, N-methyl-N- (4- (ethylcarbamoyl) benzamide, N-methyl-N- (4-methyl-carbamoyl) benzyl) benzamide, N-methyl-N- (4-methyl-carbamoyl) benzamide, N-methyl-, 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide and N-benzyl-2, 4-dihydroxy-5-isopropyl-N-methylbenzamide.

4. A pharmaceutical composition for preventing or treating a heat shock protein 90(HSP90) mediated disease, comprising a benzamide compound represented by the following chemical formula 2 or a pharmaceutically acceptable salt thereof as an active ingredient:

[ chemical formula 2]

Wherein R is₁Is halogen or C1-C4 alkyl,

R₂is that

R₃And R₄May be the same as or different from each other, and is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy,

R₅and R₆May be the same or different from each other and is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy, or R₅And R₆Are connected with each other to form a five-membered ring or a six-membered ring,

R₇is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy,

R₈is a compound of the formula (I) or a halogen,

R₉is any one selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, and benzyl.

5. The pharmaceutical composition for preventing or treating heat shock protein 90(HSP90) mediated disease as claimed in claim 4, wherein in the formula 2 TableIn the benzamide compounds shown, R₁Is halogen or C1-C4 alkyl, R₂Is thatR₃Is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy, R₉Is any one selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, and benzyl.

6. The pharmaceutical composition for the prevention or treatment of a heat shock protein 90(HSP90) mediated disease as claimed in claim 4, wherein the benzamide compound represented by chemical formula 2 is any one selected from the group consisting of: n-benzyl-5-chloro-2, 4-dihydroxybenzamide, N-benzyl-5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N- (4-methoxybenzyl) -N-methylbenzamide, 5-chloro-N- (3, 4-dimethoxybenzyl) -2, 4-dihydroxy-N-methylbenzamide, N- (benzo [ d ] [1,3] dioxol-5-ylmethyl) -5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (3,4, 5-trimethoxybenzyl) benzamide, 5-chloro-N- (2-chloro-3, 4, 5-trimethoxybenzyl) -2, 4-dihydroxy-N-methylbenzamide, N- (2-bromo-3, 4, 5-trimethoxybenzyl) -5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (3-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (2-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4- (methylcarbamoyl) benzyl) benzamide, 5-chloro-N- (4- (ethylcarbamoyl) benzyl) -2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide, 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (methylcarbamoyl) benzyl) benzamide, N- (4- (ethylcarbamoyl) benzyl) -2, 4-dihydroxy-5-isopropyl-N-methylbenzamide, N-methyl-N- (4- (ethylcarbamoyl) benzamide, N-methyl-N- (4-methyl-carbamoyl) benzyl) benzamide, N-methyl-N- (4-methyl-carbamoyl) benzamide, N-methyl-, 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide and N-benzyl-2, 4-dihydroxy-5-isopropyl-N-methylbenzamide.

7. The pharmaceutical composition for use in the prevention or treatment of a heat shock protein 90-mediated disease as claimed in any one of claims 4 to 6, wherein the heat shock protein 90-mediated disease is at least one selected from the group consisting of a cancer disease, a degenerative neurological disease and a viral infection.

8. The pharmaceutical composition of claim 7, wherein the cancer disease is any one selected from the group consisting of: non-small cell lung cancer, breast cancer, ovarian cancer, uterine cancer, pancreatic cancer, lung cancer, gastric cancer, liver cancer, colon cancer, skin cancer, head and neck cancer, brain cancer, larynx cancer, prostate cancer, bladder cancer, esophageal cancer, thyroid cancer, kidney cancer, rectal cancer, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia and leukemia.

9. The pharmaceutical composition of claim 7, wherein the degenerative neurological disease is any one selected from the group consisting of: stroke, paralysis, memory loss, memory impairment, dementia, amnesia, Parkinson's disease, Alzheimer's disease, pick's disease, Creutzfeld-Kacob disease, Huntington's disease and amyotrophic lateral sclerosis.

10. A health functional food for preventing or improving a heat shock protein 90(HSP90) mediated disease, comprising a benzamide compound represented by the following chemical formula 2 or a pharmaceutically acceptable salt thereof as an active ingredient:

[ chemical formula 2]

Wherein R is₁Is halogen or C1-C4 alkyl,

R₂is that

R₃And R₄May be the same as or different from each other, and is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy,

R₅and R₆May be the same or different from each other and is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy, or R₅And R₆Are connected with each other to form a five-membered ring or a six-membered ring,

R₇is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy,

R₈is a compound of the formula (I) or a halogen,

R₉is any one selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, and benzyl.

11. The health functional food for preventing or improving heat shock protein 90(HSP90) mediated disease according to claim 10, wherein R is in the benzamide compound represented by chemical formula 2₁Is halogen or C1-C4 alkyl, R₂Is thatR₃Is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy, R₉Is any one selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, and benzyl.

12. The health functional food for preventing or improving a heat shock protein 90(HSP90) mediated disease according to claim 10, wherein the benzamide compound represented by chemical formula 2 is any one selected from the group consisting of: n-benzyl-5-chloro-2, 4-dihydroxybenzamide, N-benzyl-5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N- (4-methoxybenzyl) -N-methylbenzamide, 5-chloro-N- (3, 4-dimethoxybenzyl) -2, 4-dihydroxy-N-methylbenzamide, N- (benzo [ d ] [1,3] dioxol-5-ylmethyl) -5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (3,4, 5-trimethoxybenzyl) benzamide, 5-chloro-N- (2-chloro-3, 4, 5-trimethoxybenzyl) -2, 4-dihydroxy-N-methylbenzamide, N- (2-bromo-3, 4, 5-trimethoxybenzyl) -5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (3-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (2-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4- (methylcarbamoyl) benzyl) benzamide, 5-chloro-N- (4- (ethylcarbamoyl) benzyl) -2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide, 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (methylcarbamoyl) benzyl) benzamide, N- (4- (ethylcarbamoyl) benzyl) -2, 4-dihydroxy-5-isopropyl-N-methylbenzamide, N-methyl-N- (4- (ethylcarbamoyl) benzamide, N-methyl-N- (4-methyl-carbamoyl) benzyl) benzamide, N-methyl-N- (4-methyl-carbamoyl) benzamide, N-methyl-, 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide and N-benzyl-2, 4-dihydroxy-5-isopropyl-N-methylbenzamide.

Technical Field

The present invention relates to a novel compound having HSP90 inhibitory activity or a pharmaceutically acceptable salt thereof and a medical use thereof.

Background

The HSP90 protein is one of the most abundant chaperones in eukaryotic cells and is responsible for the stabilization and activity regulation of various proteins associated with cell growth differentiation and survival. The HSP90 substrate protein, known as the client protein, contains more than 50 cancer-inducing proteins. HSP90 client proteins are degraded by the proteasome if HSP90 activity is inhibited.

Therefore, an inhibitor of HSP90 activity can simultaneously reduce the activity of various cancer-inducing proteins, and is therefore attracting attention as an anticancer agent that can be applied to various cancers. In particular, HSP90 has been reported to be an effective therapy for resistant cancers because it simultaneously reduces the activity of various cancer-inducing proteins.

In addition, it has been reported that HSP90 inhibitors are useful as therapeutic agents for degenerative neurological diseases, because proteins causing degenerative neurological diseases are also present in HSP90 client proteins.

HSP90 inhibitors began with the development of the natural substance Geldanamycin (GA). GA has been found to cause decomposition of Src (client protein) by inhibiting HSP90 in 1994, and inhibitors targeting HSP90 have been actively developed since then. However, GA has problems of hepatotoxicity, solubility and stability, although it has a strong anticancer effect. To remedy such problems, GA derivatives such as Tanesporin (17-AAG), alvesporin (17-DMAG) and retaspirycin were developed, but the structural features of GA have not solved the above problems. Various structural HSP90 inhibitors have been studied in the clinical stage, but since FDA approved drugs have not yet been developed, new and potent compounds are needed.

Disclosure of Invention

[ problem ] to

Accordingly, it is an object of the present invention to provide novel dihydroxyphenyl compounds or benzamide compounds.

Meanwhile, it is another object of the present invention to provide a pharmaceutical composition for preventing or treating HSP 90-mediated diseases, which comprises a novel dihydroxyphenyl compound or benzamide compound as an active ingredient.

Further, it is another object of the present invention to provide a health functional food for preventing or improving HSP90 mediated diseases, which comprises a novel dihydroxyphenyl compound or benzamide compound as an active ingredient.

[ solution ]

In order to achieve the above objects, the present invention provides a dihydroxyphenyl compound represented by the following chemical formula 1, a stereoisomer thereof, a racemic mixture thereof, or a pharmaceutically acceptable salt thereof:

[ chemical formula 1]

In the chemical formula 1, the first and second,

R₁is any one selected from the group consisting of halogen, C1-C4 alkyl, and C1-C4 alkoxy,

R₂is any one selected from the group consisting of C3-C6 cycloalkyl, phenyl, halogen, C1-C4 alkyl, and C1-C4 alkoxy, and

R₃is C1-C4 alkyl or C1-C4 alkoxy.

Meanwhile, the present invention provides a pharmaceutical composition for preventing or treating a heat shock protein 90(HSP90) -mediated disease, comprising a dihydroxyphenyl compound represented by the above chemical formula 1, a stereoisomer thereof, a racemic mixture thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.

Further, the present invention provides a health functional food for preventing or improving a heat shock protein 90(HSP90) mediated disease, comprising a dihydroxyphenyl compound represented by the above chemical formula 1, a stereoisomer thereof, a racemic mixture thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.

Further, the present invention provides a benzamide compound represented by the following chemical formula 2 or a pharmaceutically acceptable salt thereof:

[ chemical formula 2]

In the chemical formula 2, the first and second organic solvents,

R₁is halogen or C1-C4 alkyl,

R₂is that

R₃And R₄May be the same as or different from each other, and is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy,

R₅and R₆May be the same or different from each other and is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy, or R₅And R₆Are connected with each other to form a five-membered ring or a six-membered ring,

R₇is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy,

R₈is a compound of the formula (I) or a halogen,

R₉is any one selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, and benzyl.

Meanwhile, the present invention provides a pharmaceutical composition for preventing or treating a heat shock protein 90(HSP90) -mediated disease, comprising a benzamide compound represented by the above chemical formula 2 or a pharmaceutically acceptable salt thereof as an active ingredient.

In addition, the present invention provides a health functional food for preventing or improving a heat shock protein 90(HSP90) mediated disease, comprising a benzamide compound represented by the above chemical formula 2 or a pharmaceutically acceptable salt thereof as an active ingredient.

[ advantageous effects ]

As the novel compound having HSP90 inhibitory activity according to the present invention, a composition comprising a dihydroxyphenyl compound or a benzamide compound is effective in inhibiting HSP90, and thus is useful as a pharmaceutical composition for the prevention or treatment of HSP 90-mediated diseases selected from the group consisting of cancer diseases, degenerative neurological diseases and viral infections or a health functional food for the prevention or improvement of HSP 90-mediated diseases.

Drawings

Fig. 1 shows the results of confirming HSP90 inhibitory activity of compound 17 according to example 1 of the present invention.

Fig. 2A shows the results of inhibition of proliferation rate of non-small cell lung cancer cells by various concentrations of compound 17, and fig. 2B is the result of confirmation of inhibition of survival of non-small cell lung cancer cells.

Figure 3 shows the results of compound 17 inhibiting colony formation of non-small cell lung cancer cells at various concentrations.

Figure 4 shows the results of changes in protein expression after treatment with compound 17 at various concentrations on non-small cell lung cancer cells.

FIG. 5 is a graph showing the HSP90 inhibitory effect of the compound 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide of the present invention.

Detailed Description

Hereinafter, the present invention will be described in detail.

The inventors of the present invention studied a compound showing an inhibitory effect of heat shock protein 90(HSP90), synthesized a compound represented by the following formula 1, and completed the present invention by confirming its HSP90 inhibitory effect.

Accordingly, the present invention provides a dihydroxyphenyl compound represented by the following chemical formula 1, a stereoisomer thereof, a racemic mixture thereof, or a pharmaceutically acceptable salt thereof:

[ chemical formula 1]

Wherein R is₁Is any one selected from the group consisting of halogen, C1-C4 alkyl, and C1-C4 alkoxy,

R₂is any one selected from the group consisting of C3-C6 cycloalkyl, phenyl, halogen, C1-C4 alkyl, and C1-C4 alkoxy, and

R₃is C1-C4 alkyl or C1-C4 alkoxy.

In the dihydroxyphenyl compound represented by chemical formula 1, R₁Is C1-C4 alkyl, R₂Is phenyl, R₃Is a C1-C4 alkyl group.

The present invention also relates to a pharmaceutical composition for preventing or treating a heat shock protein 90(HSP90) mediated disease, comprising a dihydroxyphenyl compound represented by the following chemical formula 1, a stereoisomer thereof, a racemic mixture thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient:

[ chemical formula 1]

Wherein R is₁Is any one selected from the group consisting of halogen, C1-C4 alkyl, and C1-C4 alkoxy,

R₂is any one selected from the group consisting of C3-C6 cycloalkyl, phenyl, halogen, C1-C4 alkyl, and C1-C4 alkoxy, and

R₃is C1-C4 alkyl or C1-C4 alkoxy.

In the dihydroxyphenyl compound represented by chemical formula 1, R₁Is C1-C4 alkyl, R₂Is phenyl, R₃Is a C1-C4 alkyl group.

The heat shock protein 90-mediated disease is one or more diseases selected from the group consisting of a cancer disease, a degenerative neurological disease, and a viral infection.

The cancer may be selected from the group consisting of non-small cell lung cancer, breast cancer, ovarian cancer, uterine cancer, pancreatic cancer, lung cancer, gastric cancer, liver cancer, colon cancer, skin cancer, head and neck cancer, brain cancer, laryngeal cancer, prostate cancer, bladder cancer, esophageal cancer, thyroid cancer, kidney cancer, rectal cancer, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and leukemia, but is not limited thereto.

The degenerative neurological disease is selected from the group consisting of stroke, paralysis, memory loss, memory impairment, dementia, amnesia, Parkinson's disease, Alzheimer's disease, pick's disease, Creutzfeld-Kacob disease, Huntington's disease and amyotrophic lateral sclerosis, but is not limited thereto.

Meanwhile, the present invention relates to a health functional food for preventing or improving a heat shock protein 90(HSP90) mediated disease, which comprises a dihydroxyphenyl compound represented by the following chemical formula 1, a stereoisomer thereof, a racemic mixture thereof, or a pharmaceutically acceptable salt thereof as an active ingredient:

[ chemical formula 1]

Wherein R is₁Is any one selected from the group consisting of halogen, C1-C4 alkyl, and C1-C4 alkoxy,

R₂is any one selected from the group consisting of C3-C6 cycloalkyl, phenyl, halogen, C1-C4 alkyl, and C1-C4 alkoxy, and

R₃is C1-C4 alkyl or C1-C4 alkoxy.

Meanwhile, the present inventors also studied a compound showing the heat shock protein 90(HSP90) inhibitory effect, synthesized a compound represented by the following chemical formula 2, and confirmed its HSP90 inhibitory effect to complete the present invention.

Accordingly, the present invention provides a benzamide compound represented by the following chemical formula 2:

[ chemical formula 2]

Wherein R is₁Is halogen or C1-C4 alkyl,

R₂is that

R₃And R₄May be the same as or different from each other, and is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy,

R₅and R₆May be the same or different from each other and is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy, or R₅And R₆Are connected with each other to form a five-membered ring or a six-membered ring,

R₇is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy,

R₈is a compound of the formula (I) or a halogen,

R₉is any one selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, and benzyl.

In the benzamide compound represented by chemical formula 2, R₁Is halogen or C1-C4 alkyl, R₂Is thatR₃Is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy, and R is₉Is any one selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, and benzyl.

The benzamide compound represented by chemical formula 2 may be any one selected from the group consisting of: n-benzyl-5-chloro-2, 4-dihydroxybenzamide, N-benzyl-5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N- (4-methoxybenzyl) -N-methylbenzamide, 5-chloro-N- (3, 4-dimethoxybenzyl) -2, 4-dihydroxy-N-methylbenzamide, N- (benzo [ d ] [1,3] dioxol-5-ylmethyl) -5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (3,4, 5-trimethoxybenzyl) benzamide, 5-chloro-N- (2-chloro-3, 4, 5-trimethoxybenzyl) -2, 4-dihydroxy-N-methylbenzamide, N- (2-bromo-3, 4, 5-trimethoxybenzyl) -5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (3-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (2-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4-methylcarbamoyl) benzyl) benzamide, 5-chloro-N- (4- (ethylcarbamoyl) benzyl) -2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide, 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (methylcarbamoyl) benzyl) benzamide, N- (4- (ethylcarbamoyl) benzyl) -2, 4-dihydroxy-5-isopropyl-N-methylbenzamide, N-methyl-N- (4-ethylcarbamoyl) benzamide, N-methyl-N- (4-methyl-carbamoyl) benzyl) benzamide, N-methyl-N- (4-methyl-carbamoyl) benzamide, N-methyl-, 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide and N-benzyl-2, 4-dihydroxy-5-isopropyl-N-methylbenzamide; 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide is preferred.

In addition, the present invention also provides a pharmaceutical composition for preventing or treating a heat shock protein 90(HSP90) mediated disease, comprising a benzamide compound represented by the following chemical formula 2 or a pharmaceutically acceptable salt thereof as an active ingredient:

[ chemical formula 2]

Wherein R is₁Is halogen or C1-C4 alkyl,

R₂is that

R₃And R₄May be the same as or different from each other, and is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy,

R₅and R₆May be the same or different from each other and is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy, or R₅And R₆Are connected with each other to form a five-membered ring or a six-membered ring,

R₇is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy,

R₈is a compound of the formula (I) or a halogen,

R₉is any one selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, and benzyl.

In the benzamide compound represented by chemical formula 2, R₁May be halogen or C1-C4 alkyl, R₂Is thatR₃May be any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy, and R₉May be any one selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy and benzyl.

The benzamide compound represented by chemical formula 2 may be any one selected from the group consisting of: n-benzyl-5-chloro-2, 4-dihydroxybenzamide, N-benzyl-5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N- (4-methoxybenzyl) -N-methylbenzamide, 5-chloro-N- (3, 4-dimethoxybenzyl) -2, 4-dihydroxy-N-methylbenzamide, N- (benzo [ d ] [1,3] dioxol-5-ylmethyl) -5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (3,4, 5-trimethoxybenzyl) benzamide, 5-chloro-N- (2-chloro-3, 4, 5-trimethoxybenzyl) -2, 4-dihydroxy-N-methylbenzamide, N- (2-bromo-3, 4, 5-trimethoxybenzyl) -5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (3-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (2-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4- (methylcarbamoyl) benzyl) benzamide, 5-chloro-N- (4- (ethylcarbamoyl) benzyl) -2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide, 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (methylcarbamoyl) benzyl) benzamide, N- (4- (ethylcarbamoyl) benzyl) -2, 4-dihydroxy-5-isopropyl-N-methylbenzamide, N-methyl-N- (4- (ethylcarbamoyl) benzamide, N-methyl-N- (4-methyl-carbamoyl) benzyl) benzamide, N-methyl-N- (4-methyl-carbamoyl) benzamide, N-methyl-, 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide and N-benzyl-2, 4-dihydroxy-5-isopropyl-N-methylbenzamide; 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide is preferred.

The heat shock protein 90-mediated disease is at least one selected from the group consisting of a cancer disease, a degenerative neurological disease and a viral infection.

The cancer disease may be any one selected from the group consisting of non-small cell lung cancer, breast cancer, ovarian cancer, uterine cancer, pancreatic cancer, lung cancer, stomach cancer, liver cancer, colon cancer, skin cancer, head and neck cancer, brain cancer, larynx cancer, prostate cancer, bladder cancer, esophageal cancer, thyroid cancer, kidney cancer, rectal cancer, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and leukemia, but is not limited thereto.

The above degenerative neurological disease may be any one selected from the group consisting of stroke, paralysis, memory loss, memory impairment, dementia, amnesia, parkinson's disease, alzheimer's disease, pick's disease, Creutzfeld-Kacob disease, huntington's disease and amyotrophic lateral sclerosis, but is not limited thereto.

Further, the present invention provides a health functional food for preventing or improving a heat shock protein 90(HSP90) mediated disease, comprising a benzamide compound represented by the following chemical formula 2 or a pharmaceutically acceptable salt thereof as an active ingredient:

[ chemical formula 2]

Wherein R is₁Is halogen or C1-C4 alkyl,

R₂is that

R₃And R₄May be the same as or different from each other, and is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy,

R₅and R₆May be the same or different from each other and is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy, or R₅And R₆Are connected with each other to form a five-membered ring or a six-membered ring,

R₇is any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy,

R₈is a compound of the formula (I) or a halogen,

R₉is any one selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, and benzyl.

In the benzamide compound represented by chemical formula 2, R₁May be halogen or C1-C4 alkyl, R₂Can beR₃May be any one selected from the group consisting of H, C1-C4 alkyl and C1-C4 alkoxy, R₉Is any one selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, and benzyl.

The benzamide compound represented by chemical formula 2 may be any one selected from the group consisting of: n-benzyl-5-chloro-2, 4-dihydroxybenzamide, N-benzyl-5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N- (4-methoxybenzyl) -N-methylbenzamide, 5-chloro-N- (3, 4-dimethoxybenzyl) -2, 4-dihydroxy-N-methylbenzamide, N- (benzo [ d ] [1,3] dioxol-5-ylmethyl) -5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (3,4, 5-trimethoxybenzyl) benzamide, 5-chloro-N- (2-chloro-3, 4, 5-trimethoxybenzyl) -2, 4-dihydroxy-N-methylbenzamide, N- (2-bromo-3, 4, 5-trimethoxybenzyl) -5-chloro-2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (3-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (2-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4-methylbenzyl) benzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4- (methylcarbamoyl) benzyl) benzamide, 5-chloro-N- (4- (ethylcarbamoyl) benzyl) -2, 4-dihydroxy-N-methylbenzamide, 5-chloro-2, 4-dihydroxy-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide, 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (methylcarbamoyl) benzyl) benzamide, N- (4- (ethylcarbamoyl) benzyl) -2, 4-dihydroxy-5-isopropyl-N-methylbenzamide, N-methyl-N- (4- (ethylcarbamoyl) benzamide, N-methyl-N- (4-methyl-carbamoyl) benzyl) benzamide, N-methyl-N- (4-methyl-carbamoyl) benzamide, N-methyl-, 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide and N-benzyl-2, 4-dihydroxy-5-isopropyl-N-methylbenzamide; 2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide is preferred.

The pharmaceutical composition according to the present invention may further comprise suitable carriers, excipients or diluents commonly used for the preparation of pharmaceutical compositions.

Examples of carriers, excipients or diluents which may be used in the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate or mineral oil and the like.

The pharmaceutical composition of the present invention may be formulated into oral preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injectable solutions according to conventional methods.

In the case of formulations, diluents or excipients are used, such as the usual fillers, extenders, binders, wetting agents, disintegrants, surfactants and the like. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin and the like.

In addition to simple excipients, lubricants such as magnesium stearate and talc are used. Examples of liquid preparations for oral administration include suspensions, internal solutions, emulsions, syrups and the like; and may include various excipients such as wetting agents, sweeteners, aromatics, and preservatives, in addition to the common simple diluent water and liquid paraffin.

Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations and suppositories. Examples of non-aqueous solutions or suspensions include propylene glycol, polyethylene glycol, vegetable oils (such as olive oil), injectable esters (such as ethyl oleate), and the like. Witepsol, polyethylene glycol, Tween 61, cacao butter, laurel, glycerogelatin, etc. can be used as a base for suppository.

In addition, the dosage of the pharmaceutical composition of the present invention may be increased or decreased according to the administration route, the degree of disease, sex, body weight, age, etc. Thus, the dosage does not limit the scope of the invention in any way.

The pharmaceutical composition can be administered to mammals, such as rats, mice, livestock, humans, and the like, by various routes. All modes of administration are contemplated, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intratracheal, intrauterine or intraventricular injection.

The dihydroxyphenyl compound or benzamide compound of the present invention may be used in the form of a pharmaceutically acceptable salt, and an acid addition salt formed from a pharmaceutically acceptable free acid may be used as the salt. As the free acid, inorganic acids and organic acids can be used. As the inorganic acid, hydrochloric acid, bromic acid, sulfuric acid, sulfurous acid, phosphoric acid, or the like; as the organic acid, citric acid, acetic acid, maleic acid, fumaric acid, glycolic acid, methanesulfonic acid, acetic acid, glycolic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, embonic acid, glutamic acid, citric acid, and aspartic acid can be used. Preferably, hydrochloric acid is used as the mineral acid and methanesulfonic acid is used as the organic acid.

In addition, the dihydroxyphenyl compound or benzamide compound of the present invention includes not only pharmaceutically acceptable salts but also all salts, hydrates and solvates which can be prepared by conventional methods.

The addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving the dihydroxyphenyl compound of chemical formula 1 in a water-miscible organic solvent (e.g., acetone, methanol, ethanol, acetonitrile, etc.), adding an organic acid or adding an acidic aqueous solution of an inorganic acid, and then precipitating or crystallizing. Subsequently, the solvent or excess acid may be distilled off from the mixture and then dried to obtain further salt, or the precipitated salt may be suction filtered.

The health functional food according to the present invention may be provided in the form of powder, granules, tablets, capsules, syrup or beverage. Other foods or food additives that may be used together, in addition to the health functional foods, may be compounds represented by the above chemical formula 1 or 2, and may be appropriately used according to conventional methods. The amount of the active ingredient to be mixed may be appropriately determined depending on the purpose of its use (e.g., prevention, health or treatment).

The compound represented by chemical formula 1 or 2 contained in the health functional food may be used according to an effective dose of the pharmaceutical composition, but may be used in an amount exceeding the above range for health and hygiene purposes or for a long period of time, and as long as there is no problem in safety of the active ingredient.

The kind of the health functional food is not particularly limited. Examples of the health functional food include meat, sausage, bread, chocolate, candy, snack, pastry, pizza, stretched noodles, other noodles, chewing gum, dairy products (including ice cream), soup, beverage, tea, drink, alcoholic beverage and vitamin complex.

Hereinafter, the present invention will be described in detail with reference to the following examples. It should be noted, however, that the following examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The embodiments of the present invention are provided to more fully describe the present invention to those skilled in the art.

I. Synthesis and evaluation of biological Activity of dihydroxyphenyl Compounds

< reference example 1>

1. Reagent and laboratory equipment

All reagents and solvents were purchased from manufacturers and used without further purification.

All experiments dealing with moisture sensitive compounds were performed under argon atmosphere.

Concentration or solvent removal was performed under reduced pressure using a rotary evaporator.

Analytical thin layer chromatography was performed on precoated silica F254 TLC plates (silica F254 TLC plates, E, Merck) and UV light was visualized by staining with iodine gas.

Column chromatography can be performed on silica (Merck silica gel 40-63 μm) at moderate pressure, or in a Biotage SP1 rapid purification system (Biotage SP1) using a pre-packed silica gel small column (Biotage).

NMR analysis was carried out using ARX-300(300MHz or more) manufactured by Bruker.

Chemical shifts (δ) are recorded in parts per million. The deuterium lock signal of the sample solvent was used as reference and the coupling constant (J) was recorded in hertz (Hz).

Splitting patterns are abbreviated: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; m, multiplet.

2. Cell culture

Breast cancer cells Sk-Br3 (Korean cell line) and non-small cell lung cancer H1975 cells (ATCC) were cultured in RPMI 1640 containing 25mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) and RPMI 1640 containing L-glutamine (containing streptomycin (500mg/mL), penicillin (100 units/mL) and 10% Fetal Bovine Serum (FBS)).

Cells were incubated at 37 ℃ and 5% CO₂And culturing under a humid atmosphere.

< example 1> Synthesis of dihydroxyphenyl Compound

Compounds 5-9, compounds 10a-10i, and compounds 11a-11j were synthesized in the manner of reaction scheme 1 below.

[ reaction scheme 1]

Treatment of 2, 4-dihydroxybenzoic acid (5) with a solution of sulfuric acid in methanol gave 2, 4-dihydroxybenzoic acid ester (6) in 99% yield.

The chlorination reaction of 2, 4-dihydroxybenzoate (6) and sulfonyl chloride resulted in the formation of the chlorinated product (7) and its regioisomer methyl 3-chloro-2, 4-dihydroxybenzoate in a molar ratio of 10: 1. The regioisomers formed were carefully removed by silica gel chromatography.

Protection of compound 7 with allyl bromide in the presence of potassium carbonate gave allyl-protected ester 8 in 99% yield.

Thereafter, ester 8 was converted to carboxylic acid 9 in 97% yield using water and sodium hydroxide in methanol.

In addition, amide coupling reactions between carboxylic acid 9 and various amines were carried out in the presence of Diisopropylethylamine (DIPEA) in dichloroethane (EDC), hydroxybenzotriazole (HOBt), or Dimethylformamide (DMF) to give amides 10a-10 j.

Finally, PdCl was used under microwave irradiation₂(PPh₃)₂And ammonium formate to remove the aryl protecting group to provide compounds 11a-11 j.

[ reaction scheme 2]

Using the carboxylate 7 synthesized above, compounds 11a, 11d and 11g to 11i were obtained.

Without aryl protection, carboxylic ester 7 is converted to carboxylic acid 18 using a solution of sodium hydroxide in methanol.

[ reaction scheme 3]

Friedel-Crafts alkylation of methyl 2, 4-dihydroxybenzoate (6) was carried out using isopropyl bromide and aluminum chloride.

Compound 12 was protected with aryl bromide in the presence of potassium carbonate to give ester 13, which was converted with sodium hydroxide to give carboxylic acid 14 in 58% yield.

The amide coupling reaction of carboxylic acid 14 with 1-methyl-3-phenylpiperazine (15) in the presence of DIPEA was carried out in EDC, HOBt or DMF to give amide 16.

Finally, PdCl was used under microwave irradiation₂(PPh₃)₂And ammonium formate to remove the aryl protecting group to provide compound 17.

1.2, 4-Dihydroxybenzoic acid methyl ester (6)

A solution of 2, 4-dihydroxybenzoic acid (10.2g, 66.0mmol) and sulfuric acid (5mL) in methanol (MeOH, 40mL) was stirred with a reflux condenser at 100 ℃ for 12 h under argon. The mixture was cooled to room temperature, concentrated under pressure and poured into 40mL of H in an ice bath₂And (4) in O.

The resulting white solid was dissolved in ethyl acetate and then saturated NaHCO₃The solution was washed and filtered. The organic layer was washed with Na₂SO₄Drying and application of pressure gave compound 6 in 86% yield.

R_f0.20(2:8 ethyl acetate: hexane).¹H NMR(400MHz,CDCl₃)δ10.97(s,1H),7.74(d,J＝8.8Hz,1H),6.40(d,J＝2.0Hz,1H),6.37(dd,J＝8.8Hz,2.4Hz,1H),5.36(s,1H),3.91(s,1H).

2.5-chloro-2, 4-dihydroxybenzoic acid methyl ester (7)

Compound 6(10.0g, 59.5mmol) and sulfonyl chloride (4.30mL, 59.5mmol) in dichloromethane (CH) under argon₂Cl₂) The solution was stirred at 0 ℃ for 24 hours.

The mixture was neutralized to pH 5 with 10% NaOH, concentrated under pressure, and then extracted with ethyl acetate.

The organic layer was washed with saturated NaHCO₃Washed three times with Na₂SO₄Drying and concentration under pressure gave compound 7 in 45% yield.

R_f0.26(2:8 ethyl acetate: hexane).¹H NMR(400MHz,CDCl₃)δ10.84(s,1H),7.81(s,1H),6.61(s,1H),6.00(s,1H),3.92(s,3H).¹³C NMR(100MHz,CDCl₃)δ169.6,162.5,157.3,130.3,111.5,106.8,104.3,52.6

3.2, 4-bis (allyloxy) -5-chlorobenzoic acid methyl ester (8)

A mixture of compound 7(6.09g, 30.00mmol), aryl bromide (6.75mL, 78.02mmol) and potassium carbonate (10.78mL, 78.02mmol) in DMF was stirred at room temperature under argon for 24 h. The mixture was concentrated under pressure and extracted with ethyl acetate.

The organic layer was washed with saturated NaHCO₃Washed three times with Na₂SO₄Drying and concentration under pressure gave compound 8 in 100% yield.

R_f0.30(2:8 ethyl acetate: hexane).¹H NMR(400MHz,CDCl₃)δ7.80(s,1H),6.39(s,1H),5.99-5.91(m,2H),5.45(dd,J＝17.2Hz,1.2Hz,1H),5.39(dd,J＝17.2Hz,0.8Hz,1H),5.25(d,J＝8.0Hz,1H),5.23(d,J＝8.4Hz,1H),4.51(dd,J＝14.8Hz,5.2Hz,4H),3.77(s,3H).¹³C NMR(100MHz,CDCl₃)δ164.7,158.7,157.7,133.0,132.2,131.7,118.1,117.4,113.9,112.6,99.4,69.7,51.6

4.2, 4-bis (allyloxy) -5-chlorobenzoic acid (9)

Compound 8(9.43g, 37.99mmol) was stirred with 25ml of methanol and 25ml of aqueous sodium hydroxide (5g, 10%) at room temperature for 30 hours. The mixture was neutralized to pH 6 with 1N HCl and extracted three times with ethyl acetate.

The organic layer was washed with Na₂SO₄Drying and concentration under pressure gave compound 9 in 80% yield.

R_f0.11(4:6 ethyl acetate: hexane)An alkane).¹H NMR(400MHz,CDCl₃)δ8.16(s,1H),6.54(s,1H),6.10-5.99(m,2H),5.51-5.35(m,2H),4.76-4.65(m,4H).

5.(2, 4-bis (allyloxy) -5-chlorophenyl) (pyrrolidin-1-yl) methanone (10a)

Compound 9(0.36g, 11.33mmol), pyrrolidine (0.13mL, 1.60mmol), N' -dicyclohexylcarbodiimide (0.41g, 2.00mmol), 1-hydroxybenzotriazole (0.22g, 1.60mmol) and N, N-diisopropylethylamine (0.23mL, 1.33mmol) were dissolved in 4mL DMF and stirred under microwave irradiation (using Biotage Initiator) at 120 ℃ for 3 h.

The mixture was dissolved in ethyl acetate, the organic layer was washed with water, and Na was added₂SO₄Dried and concentrated under pressure. Thereafter, compound 10a was obtained in 65% yield using MPLC (Biotage SNAP HP-Sil column).

R_f(3:7 ethyl acetate: hexane).¹H NMR(400MHz,MeOD)δ7.26(s,1H),6.77(s,1H),6.15-6.02(m,2H),5.51(d,J＝17.2Hz,1H),5.43(d,J＝17.2Hz,1H),5.32(t,J＝11.2Hz,11.2Hz,2H),4.68(dd,J＝17.2Hz,4.4Hz,4H),3.70(t,J＝6.8Hz,6.8Hz,2H),3.33(s,2H),2.02-1.89(m,4H).¹³C NMR(100MHz,MeOD)δ167.2,155.7,154.2,132.8,132.6,128.4,119.8,116.7,116.4,114.1,99.41,69.4,69.2,45.7,33.4,25.4,24.2

(2, 4-bis (allyloxy) -5-chlorophenyl) (piperidin-1-yl) methanone (10b)

Compound 9(0.30g, 1.12mmol), piperidine (0.12mL, 1.23mmol), N' -dicyclohexylcarbodiimide (0.46g, 2.23mmol), 1-hydroxybenzotriazole (0.15g, 1.12mmol) and N, N-diisopropylethylamine (0.19mL, 1.12mmol) were dissolved in 4mL DMF and stirred under microwave radiation (Biotage Initiator) at 120 ℃ for 3 h.

The mixture was dissolved in ethyl acetate, the organic layer was washed with water, and Na was added₂SO₄Dried and concentrated under pressure. Thereafter, compound 10b was obtained in 44% yield using MPLC (Biotage SNAP HP-Sil column).

R_f0.21(3:7 ethyl acetate: hexane).¹H NMR(400MHz,CDCl₃)δ7.23(s,1H),6.67(s,1H),6.06-5.92(m,2H),5.44(d,J＝17.6Hz,1H),5.37(d,J＝17.2Hz,1H),5.31(d,J＝10.8Hz,1H),5.26(d,J＝10.4Hz,1H),5.59(d,J＝4.8Hz,2H),4.52(t,J＝4.4Hz,5.2Hz,2H),3.66(dd,J＝17.2Hz,1.6Hz,1H),3.19(dd,J＝12.0Hz,7.6Hz,2H),1.614(s,4H),1.48(d,J＝42.8Hz,2H).¹³C NMR(100MHz,CDCl₃)δ166.3,155.3,154.0,132.8,132.5,129.4,120.3,118.3,117.9,115.2,99.9,70.2,69.8,48.2,42.9,26.5,25.8,24.7.

(2, 4-bis (allyloxy) -5-chlorophenyl) (morpholino) methanone (10c)

Compound 9(0.50g, 1.85mmol), morpholine (0.18mL, 2.04mmol), N' -dicyclohexylcarbodiimide (0.76g, 3.70mmol), 1-hydroxybenzotriazole (0.55g, 1.85mmol) and N, N-diisopropylethylamine (0.32mL, 1.85mmol) were dissolved in 4mL DMF and stirred under microwave irradiation at 120 ℃ for 3 hours.

The mixture was dissolved in ethyl acetate, the organic layer was washed with water, and Na was added₂SO₄Dried and concentrated under pressure. Thereafter, compound 10c was obtained in 68% yield using MPLC (Biotage SNAP HP-Sil column).

R_f0.20(4:6 ethyl acetate: hexane)_f0.21(3:7 ethyl acetate: hexane).¹H NMR(400MHz,CDCl₃)δ7.27(s,1H),6.47(s,1H),6.07-5.93(m,2H),5.44(dd,J＝17.2Hz,1.2Hz,1H),5.36(dd,J＝17.2Hz,1.6Hz,1H),5.32(dd,J＝4Hz,2.8Hz,2H),5.29(dd,J＝10.4Hz,1.2Hz,2H),4.56(dd,J＝30.8Hz,4.0Hz,4H).

(2, 4-bis (allyloxy) -5-chlorophenyl) (4-methylpiperazin-1-yl) methanone (10e)

Compound 9(0.30g, 1.12mmol), 1-methylpiperazine (0.19mL, 1.67mmol), N' -dicyclohexylcarbodiimide (0.46g, 2.23mmol), 1-hydroxybenzotriazole (0.15g, 1.12mmol) and N, N-diisopropylethylamine (0.19mL, 1.12mmol) were dissolved in 4mL of DMF and stirred under microwave radiation (Biotage Initiator) at 120 ℃ for 3 hours.

The mixture was dissolved in ethyl acetate, the organic layer was washed with water, and Na was added₂SO₄Dried and concentrated under pressure. Thereafter, compound 10e was obtained in 64% yield using MPLC (Biotage SNAP HP-Sil column).

R_f0.14(9:1 ethyl acetate: methanol).¹H NMR(400MHz,CDCl₃)δ7.24(s,1H),6.46(s,1H),6.06-5.90(m,2H),5.43(dd,J＝17.2Hz,1.2Hz,1H),5.34(dd,J＝17.2Hz,1.2Hz,1H),5.30(dd,J＝10.4Hz,0.8Hz,1H),5.25(dd,J＝10.4Hz,1.2Hz,1H),4.58(d,J＝4Hz,2H),4.50(s,2H),3.76(d,J＝61.6Hz,2H),3.27(d,J＝15.2Hz,2H),2.27(d,J＝35.2Hz,4H),2.27(s,3H).¹³C NMR(100MHz,CDCl₃)δ166.4,155.5,154.0,132.5,132.4,129.6,119.4,118.3,118.1,115.2,99.6,70.1,69.8,55.3,54.8,46.9,46.2,41.8

9.1- (4- (2, 4-bis (allyloxy) -5-chlorophenyl) piperazin-1-yl) ethanone (10f)

Compound 9(0.30g, 1.12mmol), 1-ethylpiperazine (0.21mL, 1.67mmol), N' -dicyclohexylcarbodiimide (0.46g, 2.23mmol), 1-hydroxybenzotriazole (0.15g, 1.12mmol) and N, N-diisopropylethylamine (0.19mL, 1.12mmol) were dissolved in 4mL of DMF and stirred under microwave radiation (Biotage Initiator) at 120 ℃ for 3 hours.

The mixture was dissolved in ethyl acetate, the organic layer was washed with water, and Na was added₂SO₄Dried and concentrated under pressure. Thereafter, compound 10f was obtained in 86% yield using MPLC (Biotage SNAP HP-Sil column).

R_f0.20(9:1 ethyl acetate: methanol).¹H NMR(400MHz,CDCl₃)δ7.25(s,1H),6.46(s,1H),6.04-5.93(m,2H),5.42(dd,J＝17.2Hz,1.2Hz,1H),5.32(d,J＝15.1Hz,1H),5.26(d,J＝14.4Hz,2H),4.54(d,J＝32.8Hz,2H),3.77-3.18(m,8H),2.07(d,J＝23.6Hz,3H).

(5-chloro-2, 4-dihydroxyphenyl) (pyrrolidin-1-yl) methanone (11a)

In PdCl₂(PPh₃)₂(23mg) and 4ml of a THF solution of ammonium formate (150mg), compound 10a (0.23g, 0.72mmol) was stirred at 120 ℃ for 30 minutes under microwave irradiation.

The reaction mixture was diluted with ethyl acetate, and the organic layer was washed with water. Adding Na to the mixture₂SO₄Dried, concentrated under pressure and compound 11a was obtained in 29% yield by using MPLC.

R_f0.26(3:7 ethyl acetate: hexane).¹H NMR(400MHz,CDCl₃)δ7.20(s,1H),6.29(s,1H),4.24(s,2H),3.15(t,J＝1.6Hz,1.6Hz,4H),1.77(t,J＝6.4Hz,6.8Hz,4H).¹³C NMR(100MHz,CDCl₃)δ169.0,158.9,156.3,129.4,111.5,110.9,104.2,49.3,49.1,48.3,48.1.

(5-chloro-2, 4-dihydroxyphenyl) (piperidin-1-yl) methanone (11b)

In PdCl₂(PPh₃)₂(17mg) and 4ml of ammonium formate in THF (150mg), Compound 10b (0.17g, 0.50mmol) was stirred at 120 ℃ for 30 minutes under microwave irradiation.

The reaction mixture was diluted with ethyl acetate, and the organic layer was washed with water. Adding Na to the mixture₂SO₄Dry, concentrate under pressure, and then use MPLC to obtain compound 11b in 28% yield.

R_f0.27(5:5 ethyl acetate: hexane).¹H NMR(400MHz,MeOD)δ7.04(s,1H),6.42(s,1H),3.45(s,4H),1.62(d,J＝4.8Hz,2H),1.55(d,J＝4.4Hz,4H).¹³C NMR(100MHz,MeOD)δ169.2,156.0,154.9,129.8,116.9,112.2,104.4,36.8,34.5,26.8,25.2

(5-chloro-2, 4-dihydroxyphenyl) (morpholino) methanone (11c)

In PdCl₂(PPh₃)₂(42mg) and 4ml of ammonium formate in THF (150mg) Compound 10c (0.42g, 1.25mmol) was stirred at 120 ℃ for 30 minutes under microwave irradiation.

The reaction mixture was diluted with ethyl acetate, and the organic layer was washed with water. Adding Na to the mixture₂SO₄Dry, concentrate under pressure, and then use MPLC to obtain compound 11c in 49% yield.

R_f0.24(4:6 ethyl acetate: hexane).¹H NMR(400MHz,MeOD)δ7.16(s,1H),6.48(s,1H),3.69(d,J＝4.0Hz,4H),3.57(s,4H)

(5-chloro-2, 4-dihydroxyphenyl) (4-methylpiperazin-1-yl) methanone (11e)

In PdCl₂(PPh₃)₂(25mg) and 4ml of ammonium formate in THF (150mg) in the presence of microwave radiationCompound 10e (0.25g, 0.72mmol) was stirred at 120 ℃ for 30 min under irradiation.

The reaction mixture was diluted with ethyl acetate, and the organic layer was washed with water. Adding Na to the mixture₂SO₄Drying, concentration under pressure, and then using MPLC in two steps yielded compound 11e in 30% yield.

R_f0.20(7:3 ethyl acetate: methanol).¹H NMR(400MHz,MeOD)δ7.13(s,1H),6.47(s,1H),3.59(d,J＝8.0Hz,6H),3.52(s,2H)2.10(s,3H).¹³C NMR(125MHz,DMSO)δ165.9,154.4,153.4,128.9,116.0,109.9,103.5,54.5,45.6,40.4

14.1- (4- (5-chloro-2, 4-dihydroxybenzoyl) piperazin-1-yl) ethanone (11f)

In PdCl under microwave radiation₂(PPh₃)₂(17mg) and 4ml of a THF solution of ammonium formate (150mg), Compound 10f (0.17g, 0.45mmol) was stirred at 120 ℃ for 30 minutes.

The reaction mixture was diluted with ethyl acetate, and the organic layer was washed with water. Adding Na to the mixture₂SO₄Drying, concentration under pressure, and then using MPLC in two steps yielded compound 11f in 61% yield.

R_f0.14(9:1 ethyl acetate: methanol).¹H NMR(400MHz,MeOD)δ7.14(s,1H),6.46(s,1H),3.60(s,4H),2.51(t,J＝4.8Hz,4.8Hz,4H),2.35(s,3H).¹³C NMR(125MHz,DMSO)δ168.4,166.2,154.5,153.4,129.2,115.9,110.1,103.5,45.7,40.9,21.2

15.5-chloro-2, 4-dihydroxybenzoic acid (18)

Compound 7(1.98g, 9.76mmol) was reacted with 30ml of methanol and 30ml of sodium hydroxide in H₂The O solution (6g) was stirred at room temperature for 24 hours. The mixture was neutralized to pH 6 with 3N HCl and extracted three times with ethyl acetate.

The organic layer was washed with Na₂SO₄Drying and concentration under reduced pressure gave compound 18 in 100% yield.

¹H NMR(400MHz,CDCl₃)δ7.75(s,1H),6.40(s,1H).¹³C NMR(100MHz,CDCl₃)δ171.5,162.0,158.9,131.5,112.1,105.8,103.6.

(5-chloro-2, 4-dihydroxyphenyl) (piperazin-1-yl) methanone (11d)

Compound 18(0.21g, 1.13mmol), tert-butyl 1-piperazinecarboxylate (0.32g, 1.69mmol), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (0.46g, 2.26mmol), N' -dicyclohexylcarbodiimide (0.46g, 2.23mmol), 1-hydroxybenzotriazole (0.15g, 1.13mmol) and N, N-diisopropylethylamine (0.20mL, 1.13mmol) were dissolved in 4mL DMF and stirred under microwave irradiation at 120 ℃ for 3 hours.

The mixture was dissolved in ethyl acetate, the organic layer was washed with 1N HCl solution, Na₂SO₄Dried and concentrated under pressure. Thereafter, the intermediate compound was synthesized using MPLC (Biotage SNAP HP-Sil column) in 69% yield.

Rf is 0.23 (ethyl acetate: hexane: 5: 5).

The intermediate compound was stirred at room temperature in the presence of 10ml of 6N HCl solution and 10ml of THF for 24 hours. After the reaction was diluted with ethyl acetate, the organic layer was washed with water and Na₂SO₄Dried and concentrated under pressure. Purification by MPLC afforded compound 11d in two steps in 32% yield.

¹H NMR(400MHz,MeOD)δ7.13(s,1H),6.45(s,1H),6.45(s,1H),6.74(s,4H),3.21(d,J＝4.4Hz,4H).¹³C NMR(100MHz,MeOD)δ169.7,157.1,155.2,131.0,115.5,113.2,104.7,62.9,44.7

17.4- (5-chloro-2, 4-dihydroxybenzoyl) piperazin-2-one (11g)

Compound 18(0.30g, 1.12mmol), piperidine (0.12mL, 1.23mmol), N' -dicyclohexylcarbodiimide (0.46g, 2.23mmol), 1-hydroxybenzotriazole (0.15g, 1.12mmol) and N, N-diisopropylethylamine (0.19mL, 1.12mmol) were dissolved in 4mL DMF and stirred under microwave irradiation at 120 ℃ for 3 hours.

The reaction mixture was diluted with ethyl acetate, and the organic layer was washed with water. Adding Na to the mixture₂SO₄Dried, concentrated under pressure and using MPLC compound 11g was obtained in 44% yield.

R_f0.21(3:7 ethyl acetate: hexane).¹H NMR(400MHz,DMSO)δ10.07(s,1H),8.04(s,1H),7.09(s,1H),6.55(s,1H),3.92(s,2H),3.53(s,2H),3.36(s,3H),3.19(s,2H)

18.1- (5-chloro-2, 4-dihydroxybenzoyl) pyrrolidin-3-one (11h)

Compound 18(0.05g, 0.27mmol), 3-pyrrolidone hydrochloride (0.05g, 0.41mmol), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (0.11g, 0.55mmol), 1-hydroxybenzotriazole (0.04g, 0.27mmol), N-diisopropylethylamine (0.20mL, 1.13mmol) and N, N' -dicyclohexylcarbodiimide (0.10mL, 0.55mmol) were dissolved in 4mL DMF and stirred under microwave radiation at 120 ℃ for 3h (Biotage Initiator).

The organic layer was washed with 1N HCl solution and Na₂SO₄Drying, concentration under pressure and purification by MPLC gave compound 11h, 10% yield.

R_f0.21(5:5 ethyl acetate: hexane).¹H NMR(400MHz,CDCl₃)δ11.04(s,1H),7.39(s,1H),6.66(s,1H),5.93(s,1H),4.21(t,J＝8.0Hz,7.6Hz,2H),4.14(s,2H),2.67(t,J＝7.6Hz,8.0Hz,2H).

19.1- (5-chloro-2, 4-dihydroxybenzoyl) piperidin-4-one (11i)

Compound 18(0.20g, 1.09mmol), 4-piperidone (0.25g, 1.63mmol), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (0.42g, 2.17mmol), 1-hydroxybenzotriazole (0.15g, 1.09mmol), N-diisopropylethylamine (0.39mL, 2.17mmol) were dissolved in 4mL of DMF and stirred under microwave radiation (Biotage Initiator) at 120 ℃ for 3 hours.

The reaction mixture was diluted with ethyl acetate and the organic layer was washed with 1N HCl solution. Adding Na to the mixture₂SO₄Dried, concentrated under pressure, and then compound 11i was obtained in 3% yield by using MPLC.

R_f0.21(6:4 ethyl acetate: hexane).¹H NMR(400MHz,CDCl₃)δ10.14(s,1H),7.31(s,1H),6.67(s,1H),5.88(s,1H),3.97(t,J＝6.4Hz,6.0Hz,4H),2.58(t,J＝6.0Hz,6.4Hz,4H).

20. (5-chloro-2, 4-dihydroxyphenyl) (4-methyl-2-phenylpiperazin-1-yl) methanone (11j)

Compound 18(0.20g, 1.05mmol), 1-methyl-3-phenylpiperazine (0.28g, 1.58mmol), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (0.40g, 2.10mmol), 1-hydroxybenzotriazole (0.14g, 1.05mmol) and N, N-diisopropylethylamine (0.19mL, 1.05mmol) were dissolved in 4mL DMF and stirred under microwave radiation (Biotage Initiator) at 120 ℃ for 3 h.

The reaction mixture was diluted with ethyl acetate and the organic layer was washed with 1N HCl solution. Adding Na to the mixture₂SO₄Drying, concentration under pressure and purification by MPLC gave compound 11j in 23% yield.

R_f0.21(8:2 ethyl acetate: hexane).¹H NMR(400MHz,CDCl₃)δ7.46(d,J＝4.4Hz,2H),7.37(t,J＝7.2Hz,7.2Hz,2H),7.27(t,J＝7.2Hz,6.8Hz,1H),7.17(s,1H),6.61(s,1H),5.58(s,1H),4.24(s,1H),3.24(d,J＝12.0Hz,1H),3.22(t,J＝12.4Hz,10.4Hz,1H),2.81(d,J＝10.8Hz,1H),2.50(dd,J＝12.0Hz,4.0Hz,1H),2.32(s,3H),2.21-2.14(m,1H).

21.2, 4-dihydroxy-5-isopropylbenzoic acid methyl ester (12)

Compound 6(3.9g, 23.0mmol), 2-bromopropane (4.3mL, 46.0mmol) and aluminum chloride (6.1g, 46.0mmol) were dissolved in CH₂Cl₂Then stirred with a reflux condenser under argon, under microwave irradiation (Biotage Initiator) at 50 ℃ for 24 hours.

3-bromopropane (4.3ml, 46.0mmol) was added to the reaction mixture three times every 6 hours.

The mixture was neutralized to pH 5 with 10% NaOH, concentrated under pressure and extracted with ethyl acetate.

The organic layer was washed with saturated NaHCO₃Washed three times with Na₂SO₄Drying, concentration under pressure and purification by column afforded compound 12 in 45% yield.

R_f0.21(1:4 ethyl acetate: hexane).¹H NMR(400MHz,CDCl₃)δ10.8(s,1H),7.64(s,1H),6.34(s,1H),5.53(s,1H),3.92(s,3H),3.15-3.08(m,1H),1.25(d,J＝10.8Hz,6H).¹³C NMR(100MHz,CDCl₃)δ170.7,161.6,159.6,128.1,127.1,105.7,103.2,52.2,26.7,22.8

22.2, 4-bis (allyloxy) -5-isopropylbenzoic acid methyl ester (13)

Compound 12(2.1g, 10.3mmol), allyl bromide (2.3mL, 26.8mmol) and potassium carbonate (3.7g, 26.8mmol) were dissolved in DMF and stirred for 18 h.

The mixture was diluted with ethyl acetate and the organic layer was washed with H₂O washing with Na₂SO₄Drying and concentration under pressure gave compound 13 in 84% yield.

¹H NMR(400MHz,CDCl₃):δ7.71(s,1H),6.41(s,1H),6.10-5.97(m,2H),5.50(dd,J＝17.2Hz,1.6Hz,1H),5.41(dd,J＝17.2Hz,1.2Hz,1H),5.27(d,J＝10.8Hz,2H),4.56(dd,J＝9.6Hz,4.8Hz,4H),3.84(s,1H),3.26-3.19(m,1H),1.19(d,J＝6.8Hz,6H).

23.2, 4-bis (allyloxy) -5-isopropylbenzoic acid (14)

Compound 13(2.5g, 8.6mmol) is reacted with 30ml of methanol and 30ml of sodium hydroxide in H₂The O solution (1.7g, 43.1mmol) was stirred at room temperature for 24 hours.

The mixture was diluted with ethyl acetate and the organic layer was washed with 3N HCl solution and Na₂SO₄Drying, concentration under pressure and purification on column afforded compound 14 in 58% yield.

R_f0.18(1:4 ethyl acetate: hexane).¹H NMR(400MHz,CDCl₃):δ7.97(s,1H),6.43(s,1H),6.10-5.97(m,2H),5.47-5.39(m,2H),5.30(d,J＝10.8Hz,2H),4.73(d,J＝5.6Hz,2H),4.57(d,J＝4.8Hz,2H),3.26-3.19(m,1H),1.18(d,J＝6.8Hz,6H).

(2, 4-bis (allyloxy) -5-isopropylphenyl) (4-methyl-2-phenylpiperazin-1-yl) methanone (16)

Compound 14(0.18g, 0.66mmol), 1-methyl-3-phenylpiperazine (0.18g, 0.99mmol), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (0.25g, 1.33mmol), 1-hydroxybenzotriazole (0.09g) and N, N-diisopropylethylamine (0.09mL, 0.66mmol) were dissolved in 4mL of DMF and stirred under microwave radiation (Biotage Initiator) at 120 ℃ for 3 hours.

The reaction mixture was diluted with ethyl acetate, and the organic layer was washed with waterWashed with 1N HCl solution. Adding Na to the mixture₂SO₄Drying, concentration under pressure and purification by MPLC afforded compound 16 in 92% yield.

R_f0.24(3:7 ethyl acetate: hexane).

(2, 4-dihydroxy-5-isopropylphenyl) (4-methyl-2-phenylpiperazin-1-yl) methanone (17)

In PdCl₂(PPh₃)₂(10mg) and 4ml of ammonium formate in THF (227mg), Compound 16(0.26g, 0.61mmol) was stirred under microwave radiation at 120 ℃ for 30 minutes.

The reaction mixture was diluted with ethyl acetate, and the organic layer was washed with water. Adding Na to the mixture₂SO₄Drying, concentration under pressure, and then using MPLC in two steps yielded compound 17 in 15% yield.

R_f0.32(8:2 ethyl acetate: hexane).¹H NMR(400MHz,CDCl₃):7.45(d,J＝7.6Hz,2H),7.37(t,J＝7.2Hz,7.6Hz,2H),7.25(t,J＝7.8Hz,7.6Hz,1H),6.99(s,1H),6.40(s,1H),5.58(s,1H),4.24(s,1H),3.44(t,J＝8.8Hz,12.0Hz,1H),3.30(t,J＝12.4Hz,10.4Hz,1H),3.05-3.00(m,1H),2.79(d,J＝10.8Hz,1H),2.47(dd,J＝12.0Hz,4.0Hz,1H),2.30(s,3H),2.22-2.16(m,1H),0.95(dd,J＝20.0Hz,6.0Hz,6H).¹³C NMR(100MHz,CDCl₃)δ171.5,158.1,138.8,128.9,127.3,127.1,126.4,109.1,103.9,60.6,55.4,45.6,26.1,22.5,21.1,19.9,14.3

< example 2> evaluation of biological Activity of dihydroxyphenyl Compound

1. Confirmation of HSP90 inhibitory Effect

The HSP90 inhibitory effect of the dihydroxyphenyl compound synthesized in example 1 was confirmed by fluorescence polarization assay (FP assay).

HFB buffer (100mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) pH 7.3, 2M KCl, 1M MgCl₂、1M Na₂MoO₄100% NP4O), HSP 90. alpha. N-terminal domain (2. mu.M) protein, FITC (fluorescein isothiocyanate) labeled Geldanamycin (GA) inhibitor (500nM) and various concentrations (0.001. mu.M, 0.01. mu.M, 0.1. mu.M, 0.5. mu.M, 1. mu.M, 5. mu.M, 10. mu.M, 50. mu.M, 100. mu.M) of the compoundThe material was added to each well.

Thereafter, the plates were incubated at 4 ℃ for 14 hours. Polarization values in millipolarization units (millipolarization units) were measured at an excitation wavelength of 495nm and an emission wavelength of 530 nm.

All experimental data were analyzed using Prism Software (version 5.0, Graphpad Software, San Diego, CA). In addition, the measured values of tPSA (topological polar surface area) and LogP calculated using Chemdraw software are shown in tables 1 and 2 below.

[ chemical formula 3]

Compounds 11a to 11i are represented by chemical formula 3.

[ Table 1]

[ chemical formula 4]

Compounds 11j and 17 are represented by the above chemical formula 4.

[ Table 2]

As a result, IC of compound 17 against HSP90 was shown in Table 2₅₀IC at 0.0495. mu.M, H1975₅₀98 μ M.

In addition, HSP90 inhibitory activity of compound 17 confirmed by FP analysis is shown in fig. 1. Elevated concentrations of compound 17 increased the FITC-geldanamycin/HSP 90 alpha (N-terminal domain) protein response and FP readings were recorded.

As shown in table 2, compound 17 showed HSP90 inhibitory activity in a concentration-dependent manner.

2. Confirmation of cell proliferation and survival inhibition

Next, non-metastatic lung cancer cells were treated with compound 17 and cell proliferation rate or cell viability was measured by MTS [3- (4, 5-dimethylthiazol-2-yl) -5- (3-carboxymethoxyphenyl) -2- (4-sulfophenyl) -2H-tetrazolium, inner salt ] assay.

Cells were distributed in 96-well plates at 3000 cells/well (Sk-Br3) and 2000 cells/well (H1975), 100. mu.L of medium was added to each well, and then incubated overnight.

The following day, compound 17 or 1% DMSO vehicle (control) was added to each well at a concentration of 0, 0.01 μ M, 0.1 μ M, 1 μ M, 5 μ M, 10 μ M, 30 μ M, 50 μ M, or 70 μ M, and incubated at 37 ℃ for 1 day, 2 days, and 3 days.

Cell proliferation was assessed using the Promega Cell Titer 96Aqueous One Solution Cell proliferation assay.

After compound and cell culture, 20 μ L of assay substrate solution was added to each well and incubated for an additional 1 hour at 37 ℃.

Cell proliferation was confirmed by measuring absorbance at 490nm using a microplate reader (Tecan Infinite F200 Proplate reader).

Compound 17 or 1% DMSO vehicle (control group) was added to each well at a concentration of 0, 0.01. mu.M, 0.1. mu.M, 1. mu.M, 5. mu.M, 10. mu.M, 30. mu.M, 50. mu.M or 70. mu.M, and incubated at 37 ℃ for 72 hours and absorbance was measured at 490nm, the measured value being expressed as a percentage of the absorbance of cells cultured with DMSO only, to confirm cell survival.

As a result, as shown in fig. 2, the proliferation rate of cells was inhibited in a concentration-dependent manner of compound 17 with the lapse of time (fig. 2A), and cell death was also observed (fig. 2B).

3. Confirmation of H1975 colony formation inhibitory Effect

H1975 cells were treated with Compound 17 at a concentration of 0.05. mu.M or 0.5. mu.M for 3 weeks, followed by a clonogenic assay (clonal assay).

First, RPMI 1640 medium (10% FBS, 0.48% agar) was added to a 6-well plate and hardened, and then 10000 cells (H1975) were dispensed into a medium containing RPMI 1640 medium (10% FBS, 0.33% agar) and solidified. After solidification, the cells were treated with the compound at a concentration of 0.05. mu.M or 0.5. mu.M for 24 hours, followed by culturing for 3 weeks, and then colony formation was confirmed with a crystal violet staining solution.

The results are shown in FIG. 3, and compound 17 inhibits colony formation of H1975 even at low concentrations of 0.05. mu.M.

4. Protein expression analysis

Recombinant HSP90 was expressed from pET-15b plasmid (Novagen) into E.coli BL21(DE3) cells (BioLabs).

New colonies were grown using LB broth containing 2.5mg/mL (500. mu.l/200 mL) of ampicillin, shaking at 180rpm, until the absorbance reached A₆₀₀＝0.5。

Thereafter, protein expression was induced by isopropyl-1-thio- β -D-galactopyranoside (final concentration 1 mM).

After the temperature was lowered to 18 ℃ the cells were incubated overnight with shaking and the cell pellet (cell pellet) was obtained by centrifugation (4000rpm, 20 min, 4 ℃).

The cell pellet was suspended in NTA (nitrilotriacetic acid) buffer (containing 20mM Tris pH8.0, 0.5M NaCl), sonicated in ice and centrifuged to obtain supernatant (14000rpm, 99 min, 4 ℃).

His-tagged proteins were purified using Histidine Trap column and nickel-nitriloacetic acid and separated by FPLC (fast protein liquid chromatography: pharmacia).

To identify HSP proteins, the proteins were analyzed by western blotting (western blotting).

Salts were removed from the purified protein by PD10 column and concentrated to 2.4mg/ml in Vivaspin 20 and stored at-70 ℃.

Next, the cells were distributed to 100mm culture dishes (1X 10)⁶/dish) and adhered to the bottom surface overnight. Compound 17 was added to the cells at a concentration of 0.05. mu.M, 0.1. mu.M, 0.5. mu.M or 1. mu.M, followed by further incubation for 24 hours.

In addition, cells were treated with DMSO (1%) or geldanamycin (1 μ M) as a control and cultured for 24 hours.

Cultured cells were harvested and lysed in ice-cold lysis buffer (23mM Tris-HCl pH 7.6, 130mM NaCl, 1% NP40, 1% sodium deoxycholate, 0.1% SDS (sodium dodecyl sulfate)), and 30. mu.g of the lysate was separated by SDS-PAGE (SDS-polyacrylamide gel electrophoresis) and transferred to PVDF membrane (Bio-Rad).

Membranes were blocked with TBST (tween 20 containing Tris buffered saline) containing 5% skim milk and incubated with each of the primary antibodies [ EGFR (epidermal growth factor receptor), Her2 (human epidermal growth factor receptor type 2), Met, N-cadherin, E-cadherin, alpha-tubulin, acetyl-alpha-tubulin, protein kinase B (akt), c-Raf, Cdk4 (cyclin dependent kinase 4), HSP90, HSP70, PARP (poly ADT-ribose polymerase), caspase 3, cleaved caspase 3, truncated caspase 8, B-Cell lymphoma 2(Bcl-2), Bax or beta-actin, available from Cell Signaling Technology (USA) ].

After binding to horseradish peroxidase conjugated secondary antibodies, the proteins were visualized by ECL (electrochemiluminescence, GE healthcare, USA).

Results as shown in figure 4, compound 17 inhibited HSP proteins in a concentration-dependent manner to confirm degradation of HSP90 client proteins of EGFR, Her2, Met, Akt, c-Raf, Cpk4, and most of the client proteins were denatured at 500 nM.

Evaluation of Synthesis and biological Activity of benzamide Compounds

< reference example 2> reagent and Experimental apparatus

Reagents from Sigma-Aldrich (St. Louis, MO, USA), Acros Organics (Thermo Fisher Scientific In, Gell, Belgium), Alfa Aesar (A Johnson Mattey Company, Karlsruhe, Germany) and Daejung (Daejeon ghwagegum Co., Kyunggi-do, Korea) were used. The compound synthesis is carried out in argon or in the atmosphere, in some cases using microwaves (A), (B), (CUppsala, Sweden). Extraction, recrystallization, column chromatography and MPLC (Medium pressure liquid chromatography) for purifyingAnd purifying the synthesized product. Silica gel 60(0.040-0.063mm) was used as a packing for column chromatography, and a SNAP small column (KP-Sil 25g or KP-C18-HS 30g) was used for MPLC.

The sample was used by Bruker spectrospin 400 spectrometer (Bruker co, Billerica, Massachusetts, USA)¹H NMR and¹³c NMR spectroscopy identified the structure of each compound. Using CDCl₃、CD₃OD or dimethyl sulfoxide (DMSO) -d₆As the solvent, the chemical shift value (. delta.) is expressed in ppm, and the peaks are expressed by d (doublet), t (triplet), m (multiplet) and dd (doublet).

The biological activity was assessed using a power supply (BioRad co, Hercules, CA), an image analyser (Fuji, Tokyo, Japan) and a microplate reader (TECAN, Mannedorf, Switerland).

< example 3> Synthesis of benzamide Compound

Compounds 6a-6h and 8a-8c were synthesized in the same manner as in reaction scheme 4 below.

[ reaction scheme 4]

1. Amine Synthesis method I (6a-h)

1 equivalent of each aldehyde and 1.5 equivalents of 40% aqueous methylamine distilled solution were dissolved in MeOH and stirred at room temperature for 30 minutes. Slowly add 0.5 equivalents of sodium borohydride (NaBH) at 0 deg.C₄) And then stirred for 1 hour. Thereafter, H is added₂O was added to the mixture, MeOH was removed by distillation under reduced pressure, and extracted three times with Dichloromethane (DCM). The DCM layer was washed with Na₂SO₄Drying and filtration, and removal of the solvent by distillation under reduced pressure gave 6a-h in 32.0-76.4% yield.

2. Amine Synthesis method II (8a-c)

1 equivalent of benzoic acid, 1.5 equivalents of 40% methylamine are distilledAn aqueous solution, 2 equivalents of EDC (1-ethyl-3- (3-dimethylaminopropyl) carbodiimide) or DCC (N, N-dicyclohexylcarbodiimide), 1 equivalent of HOBt (hydroxybenzotriazole) and 1 equivalent of DIPEA (N, N-diisopropylethylamine) were dissolved in Dimethylformamide (DMF) and subjected to microwave reaction at 120 ℃ and 20bar for 3 hours. Dissolved in Ethyl Acetate (EA) and washed several times with 1N HCl-saturated aqueous solution, and the EA layer was washed with Na₂SO₄Dried and filtered, and the solvent was removed by distillation under reduced pressure. After purification by MPLC or column chromatography, 1 equivalent of the purified compound was dissolved in Tetrahydrofuran (THF), 3 equivalents of Lithium Aluminum Hydride (LAH) were slowly added at 0 deg.C and stirred for 12 hours. Saturated aqueous solution with 10% NaOH and H₂The reaction was quenched and extracted with ether. The ether layer was washed with Na₂SO₄Dried and filtered, and the solvent was distilled off under reduced pressure. After purification by column chromatography 8a-c was obtained in 22.5%, 88.7% yield.

Compounds 14a-14i were synthesized in the same manner as in reaction scheme 5 below.

[ reaction scheme 5]

3.2, 4-Dihydroxybenzoic acid methyl ester (9)

2, 4-Dihydroxybenzoic acid (10.00g, 64.88mmol) and 5mL of sulfuric acid (H)₂SO₄) Added to 40mL MeOH and refluxed at 100 deg.C for 24 hours. After cooling at room temperature, the solvent was removed by distillation under reduced pressure and H was added at 0 deg.C₂And O. The resulting white solid was dissolved in EA and saturated NaHCO₃And (4) washing with an aqueous solution. Mixing EA layer with Na₂SO₄Drying and filtration, and removal of the solvent by distillation under reduced pressure gave compound 9 in 85% yield.

¹H NMR(400MHz,CDCl₃)d 11.0(s,1H),7.73(d,J＝8.4Hz,1H),6.41-6.37(m,2H),5.78(s,1H),3.92(s,3H).

4.5-chloro-2, 4-dihydroxybenzoic acid methyl ester (10)

Compound 8(8.30g, 49.41mmol) and sulfonyl chloride (SO)₂Cl₂) (4.11mL, 56.83mmol) was added to DCM and stirred at room temperature for 24 h. Removing the solvent by distillation under reduced pressure, dissolving in EA, and adding saturated NaHCO₃Washing with aqueous solution, and adding Na₂SO₄Dried and filtered, and the solvent was removed by distillation under reduced pressure. Purification by column chromatography using a solvent mixture of EA: hexane ═ 1:9 gave compound 10 in 32.5% yield.

¹H NMR(400MHz,CDCl₃)d 10.8(s,IH),7.82(s,IH),6.61(s,IH),5.91

5.2, 4-bis (allyloxy) -5-chlorobenzoic acid methyl ester (11)

Compound 9(1.10g, 5.46mmol), allyl bromide (1.23mL, 14.20mmol) and K₂CO₃(1.96g, 14.20mmol) was dissolved in DMF. It was stirred at room temperature for 12 hours under argon, then dissolved in EA and saturated NaHCO₃And (4) washing with an aqueous solution. Mixing EA layer with Na₂SO₄Drying and distillation under reduced pressure removed the solvent to give compound 11 in 83% yield.

¹H NMR(400MHz,CDCl₃)d 7.85(s,1H),7.25(s,1H),6.44-5.95(m,2H),5.50-5.40(m,2H),5.30-5.26(m,2H),4.58-4.45(m,4H),3.81(s,3H).

6.2, 4-bis (allyloxy) -5-chlorobenzoic acid (12)

Compound 8(1.27g, 5.64mmol) and NaOH (1.12g, 28.1mmol) are added to H₂O (20mL) and MeOH (20mL) and stirred at room temperature for 8 hours, then dissolved in EA and washed with 3N HCl. Mixing EA layer with Na₂SO₄Drying and then removing the solvent by distillation under reduced pressure gave compound 12 in 74% yield.

¹H NMR(400MHz,CDCl₃)d 8.16(s,1H),6.54(s,1H),6.10-5.99(m,2H),5.51-5.35(m,2H),4.76-4.65(m,4H).

N-benzyl-5-chloro-2, 4-dihydroxybenzamide (14a)

Compound 12(0.50g, 1.86mmol), benzylamine (0.26g, 1.86mmol), HOBt (0.25g, 1.86mmol), DCC (0.77g, 3.72mmol) and DIPEA (0.32mL, 1.86mmol) were dissolved in DMF and the microwave reaction was carried out at 80 ℃ and 20bar for 3 hours. DMF was removed by distillation under reduced pressure and passed through MPLC (R)_f0.19, EA: hexane: 1:4) to afford compound 13 a. Compound 13a was dissolved in THF, and PdCl was added thereto₂(PPh₃)₂(20mg) and NH₄HCO₃(200mg) and then reacted with a microwave at 120 ℃ and 20bar for 30 minutes.

Dissolving it in EA with H₂O washing, and Na washing the EA layer₂SO₄Dried and then filtered. Removing the solvent by distillation under reduced pressure, using MPLC (R)_f0.13, EA: hexane: 3:7) to give compound 14a in 53.2% yield.

¹H NMR(400MHz,MeOD)d 7.77(s,1H),7.29-7.26(m,4H),7.22-7.19(m,1H),6.40(s,1H),4.50(s,2H).¹³C NMR(100MHz,MeOD)d165.2,157.0,154.2,135.3,125.2,124.7,123.7,123.4,108.1,104.9,100.2,39.1.

N-benzyl-5-chloro-2, 4-dihydroxy-N-methylbenzamide (14b)

Compound 12(0.30g, 1.12mmol), compound 6a (0.21g, 1.67mmol), HOBt (0.15g, 1.12mmol), DCC (0.46g, 2.23mmol) and DIPEA (0.19mL, 1.12mmol) were dissolved in DMF and the microwave reaction was carried out at 80 ℃ and 20bar for 3 hours. Then dissolving it in EA and using H₂O washing, and Na washing the EA layer₂SO₄Dried and filtered, and then the solvent was removed by distillation under reduced pressure. By MPLC (R)_f0.31, EA: hexane: 3:7) to give compound 13 b. Compound 13b was dissolved in THF, and PdCl was added thereto₂(PPh₃)₂(20mg) and NH₄HCO₃(200mg) and then reacted with a microwave at 120 ℃ and 20bar for 30 minutes. Dissolved in EA and treated with H₂After O-washing, the EA layer was washed with Na₂SO₄Dried and filtered, and the solvent was removed by distillation under reduced pressure. By MPLC (R)_f0.28, EA: hexane: 2:3) to obtain compound 14b in 62.5% yield.

¹H NMR(400MHz,MeOD)d 7.35-7.24(m,5H),7.16(s,1H),6.50(s,1H),2.89(s,3H).

9.5-chloro-2, 4-dihydroxy-N- (4-methoxybenzyl) -N-methylbenzamide (14c)

Compound 12(0.30g, 1.12mmol), compound 6b (0.18g, 1.67mmol), HOBt (0.15g, 1.12mmol), DCC (0.46g, 2.23mmol) and DIPEA (0.19mL, 1.12mmol) were dissolved in DMF and the microwave reaction was carried out at 80 ℃ and 20bar for 3 hours. DMF was distilled off under reduced pressure and purified by MPLC to give compound (R)_f0.20, EA: hexane: 3: 7). Compound 13c was dissolved in THF, and PdCl was added thereto₂(PPh₃)₂(20mg) and NH₄HCO₃(200mg) and then reacted with a microwave at 120 ℃ and 20bar for 30 minutes. Dissolved in EA and treated with H₂After O-washing, the EA layer was washed with Na₂SO₄Dried and filtered, and the solvent was removed by distillation under reduced pressure.

By MPLC (R)_f0.30, EA: hexane: 2:3) to give compound 14c in 63.8% yield.

¹H NMR(400MHz,CDCl₃)d 7.27(s,1H),7.20(d,J＝8.4Hz,2H),6.90(d,J＝6.8Hz,2H),6.62(s,1H),4.64(s,2H),3.80(s,3H),3.03(s,3H).¹³C NMR(100MHz,CDCl₃)d 171.1,159.6,159.3,155.2,129.0,128.8,128.0,114.4,111.1,110.5,105.2,55.4.

10.5-chloro-N- (3, 4-dimethoxybenzyl) -2, 4-dihydroxy-N-methylbenzamide (14d)

Compound 12(0.33g, 1.23mmol), compound 6c (0.33g, 1.84mmol), HOBt (0.17g, 1.23mmol), DCC (0.51g, 2.46mmol) and DIPEA (0.22mL, 1.23mmol) were dissolved in DMF and the microwave reaction was carried out at 120 ℃ and 20bar for 3 hours. By MPLC (R)_f0.26, EA: hexane: 2:3) to yield compound 13 d. Compound 13d was dissolved in THF, and PdCl was added thereto₂(PPh₃)₂(20mg) and NH₄HCO₃(200mg) and then reacted with a microwave at 120 ℃ and 20bar for 30 minutes. Dissolved in EA and treated with H₂After O-washing, the EA layer was washed with Na₂SO₄Drying and filtering, and passingThe solvent was distilled off under reduced pressure. By MPLC (R)_fPurification of 0.22 EA hexanes 1:1) gave compound 14d in 63.8% yield.

¹H NMR(400MHz,CDCl₃)d 7.31(s,1H),6.88-6.81(m,3H),6.66(s,1H),4.65(s,2H),3.88(d,J＝6.4Hz,6H),3.07(s,3H).¹³C NMR(100MHz,CDCl₃)d 170.5,155.3,149.1,148.3,131.9,131.8,128.8,128.7,128.6,128.5,119.3,111.0,110.5,105.1,55.7.

N- (benzo [ d ] [1,3] dioxol-5-ylmethyl) -5-chloro-2, 4-dihydroxy-N-methylbenzamide (14e)

Compound 12(0.30g, 1.12mmol), compound 6d (0.28g, 1.67mmol), HOBt (0.15g, 1.12mmol), DCC (0.46g, 2.23mmol) and DIPEA (0.19mL, 1.12mmol) were dissolved in DMF and the microwave reaction was carried out at 80 ℃ and 20bar for 3 hours. DMF was removed by distillation under reduced pressure and then passed through MPLC (R)_f0.25, EA: hexane: 3:7) to afford compound 13 e. Compound 13e was dissolved in THF and PdCl was added₂(PPh₃)₂(20mg) and NH₄HCO₃(200mg) and then reacted with a microwave at 120 ℃ and 20bar for 30 minutes. Dissolving in EA and using H₂After O-washing, the EA layer was washed with Na₂SO₄Dried and filtered, the solvent removed by distillation under reduced pressure, purified by MPLC (R)_f0.23, EA: hexane: 2:3) gave compound 14e in 78.6% yield.

¹H NMR(400MHz,CDCl₃)d 7.28(s,1H),6.79-6.72(m,3H),6.60(s,1H),5.96(s,2H),4.59(s,2H),3.03(s,3H).¹³C NMR(100MHz,CDCl₃)d

12.5-chloro-2, 4-dihydroxy-N-methyl-N- (3,4, 5-trimethoxybenzyl) benzamide (14f)

Compound 12(0.30g, 1.12mmol), compound 6e (0.35g, 1.23mmol), HOBt (0.15g, 1.12mmol), DCC (0.46g, 2.23mmol) and DIPEA (0.19mL, 1.12mmol) were dissolved in DMF and the microwave reaction was carried out at 80 ℃ and 20bar for 3 hours. By MPLC (R)_f0.20, EA: hexane: 2:3) to yield compound 13 f. Compound 13f was dissolved in THF, and PdCl was added thereto₂(PPh₃)₂(20mg) and NH₄HCO₃(200mg) and then reacted with a microwave at 120 ℃ and 20bar for 30 minutes. Dissolving in EA and using H₂After O-washing, the EA layer was washed with Na₂SO₄Drying and filtering, removing the solvent by distillation under reduced pressure, passing MPLC (R)_f0.26, EA: hexane: 3:2) purification afforded compound 14f in 67.0% yield.

¹H NMR(400MHz,CDCl₃)d 7.23(s,1H),6.56(s,1H),6.47(s,1H),4.59(s,2H),3.80(d,J＝1.2Hz,9H),3.02(s,3H).¹³C NMR(100MHz,CDCl₃)d 171.2,158.7,155.4,153.6,137.3,132.0,128.8,111.6,110.8,105.1,104.5,61.0,56.2.

13.5-chloro-N- (2-chloro-3, 4, 5-trimethoxybenzyl) -2, 4-dihydroxy-N-methylbenzamide (14g)

Compound 12(0.20g, 0.74mmol), compound 6f (0.27g, 1.12mmol), HOBt (0.10g, 0.74mmol), DCC (0.31g, 1.49mmol) and DIPEA (0.15mL, 0.74mmol) were dissolved in DMF and the microwave reaction was carried out at 120 ℃ and 20bar for 3 hours. Washing with EA and with H₂After O-washing, the EA layer was washed with Na₂SO₄Drying, filtering, and removing the solvent by distillation under reduced pressure, passing MPLC (R)_f0.26, EA: hexane: 3:7) to yield 13g of compound. 13g of the compound was dissolved in THF, PdCl was added₂(PPh₃)₂(20mg) and NH₄HCO₃(200mg) and then reacted at 120 ℃ and 20bar for 30 minutes with a microwave over Na₂SO₄Dried and filtered, and the solvent was removed by distillation under reduced pressure. By MPLC (R)_fPurification of 0.20, EA: hexane: 1) gave 14g of compound in 41.9% yield.

¹H NMR(400MHz,CDCl₃)d 7.21(s,1H),6.75(s,1H),6.47(s,1H),4.75(s 2H),3.90(d,J＝9.2Hz,6H),3.83(s,3H),3.03(s,3H).¹³C NMR(100MHz,CDCl₃)d 171.1,156.3,155.4,152.5,150.0,142.4,132.0,129.3,128.9,119.2,113.0,111.3,107.0,104.2,61.2,56.1,49.8.

N- (2-bromo-3, 4, 5-trimethoxybenzyl) -5-chloro-2, 4-dihydroxy-N-methylbenzamide (14h)

Mixing Compound 12 (0)19g, 0.69mmol), 6g (0.30g, 1.03mmol) of compound, HOBt (0.09g, 0.69mmol), DCC (0.28g, 1.38mmol) and DIPEA (0.12mL, 0.69mmol) were dissolved in DMF and the microwave reaction was carried out at 120 ℃ and 20bar for 3 hours. Dissolved in EA and treated with H₂After O-washing, the EA layer was washed with Na₂SO₄Dried and filtered, and the solvent was removed by distillation under reduced pressure. By MPLC (R)_f0.24, EA: hexane: 3:7) to yield compound 13 h.

The compound was dissolved in THF for 13h, and PdCl was added thereto₂(PPh₃)₂(20mg) and NH₄HCO₃(200mg) and then reacted with a microwave at 120 ℃ and 20bar for 30 minutes. Dissolved in EA and treated with H₂After O-washing, the EA layer was washed with Na₂SO₄Dried and filtered, and the solvent was removed by distillation under reduced pressure. By MPLC (R)_fPurification of 0.24, EA: hexane: 1) gave compound 14h with 20.5% yield.

¹H NMR(400MHz,CDCl₃)d 7.15(s,1H),6.69(s,1H),6.42(s,1H),4.68(s,2H),3.83(d,J＝6.0Hz,6H),3.77(d,3H),2.98(s,3H).¹³C NMR(100MHz,CDCl₃)d 160.8,155.2,153.4,151.4,143.0,130.9,128.6,110.7,110.3,105.4,61.4,61.3,60.7,56.5.

15.5-chloro-2, 4-dihydroxy-N-methyl-N- (3-methylbenzyl) benzamide (14i)

Compound 12(0.25g, 0.93mmol), compound 6h (0.19g, 1.40mmol), HOBt (0.13g, 0.93mmol), DCC (0.39g, 1.86mmol) and DIPEA (0.17mL, 0.93mmol) were reacted in DMF by microwave at 120 ℃ and 20bar for 3 h. Dissolving in EA and using H₂After O-washing, the EA layer was washed with Na₂SO₄Drying and filtering, removing the solvent by distillation under reduced pressure, passing MPLC (R)_f0.22, EA: hexane: 1:4) to yield compound 13 i.

Compound 13i was dissolved in THF, and PdCl was added thereto₂(PPh₃)₂(20mg) and NH₄HCO₃(200mg) and the microwave reaction was carried out at 120 ℃ and 20bar for 30 minutes. Dissolving in EA and using H₂After O-washing, the EA layer was washed with Na₂SO₄DryingFiltering, removing solvent by distillation under reduced pressure, and passing through MPLC (R)_f0.20, EA: hexane: 3:7) to afford compound 14i in 68.7% yield.

¹H NMR(400MHz,CDCl₃)d 7.31(s,1H),7.28(d,J＝7.6Hz,1H),7.15(d,J＝7.6Hz,1H),7.10-7.09(m,2H),6.65(s,1H),4.70(s,2H),3.08(s,3H),2.38(s,3H).¹³C NMR(100MHz,CDCl₃)d 171.3,160.0,155.2,138.8,136.0,128.9,128.8,128.7,128.3,124.6,110.9,110.4,105.2,36.8.

Compounds 16a and 16b were synthesized in the same manner as in the following reaction scheme 6.

[ reaction scheme 6]

16.5-chloro-2, 4-dihydroxybenzoic acid (15)

Compound 9(1.98g, 9.77mmol) and NaOH (1.95g, 48.80mmol) were added to H₂O (30mL) and MeOH (30mL) and stirred at room temperature for 12 h. It was dissolved in EA, washed with 3N HCl saturated aqueous solution, and the EA layer was washed with Na₂SO₄Dried and filtered. The solvent was removed by distillation under the reduced pressure and purified by MPLC to give compound 15 in 100% yield.

¹H NMR(400MHz,CDCl₃)d 7.76(s,1H),6.41(s,1H).

17.5-chloro-2, 4-dihydroxy-N-methyl-N- (2-methylbenzyl) benzamide (16a)

Compound 15(0.17g, 0.92mmol), compound 8a (0.19g, 1.40mmol), HOBt (0.12g, 0.92mmol), EDC (0.35g, 1.86mmol) and DIPEA (0.16mL, 0.92mmol) were dissolved in DMF and the microwave reaction was carried out at 120 ℃ and 20bar for 3 h. It was dissolved in EA, washed with 1N HCl saturated aqueous solution and Na₂SO₄Dried and filtered. The solvent was distilled off under reduced pressure. By MPLC (R_f0.23, EA: hexane: 1:4) to give compound 16a in 90.5% yield.

¹H NMR(400MHz,CDCl₃)d 7.25-7.24(m,4H),6.65(s,1H),4.72(s,2H),3.07(s,3H),2.27(s,3H).¹³C NMR(100MHz,CDCl₃)d 160.9,155.2,136.4,134.0,131.0,128.7,128.0,127.4,126.7,110.7,110.2,105.3,19.2.

18.5-chloro-2, 4-dihydroxy-N-methyl-N- (4-methylbenzyl) benzamide (16b)

Compound 15(0.21g, 1.12mmol), compound 8b (0.23g, 1.69mmol), HOBt (0.15g, 1.12mmol), EDC (0.43g, 2.25mmol) and DIPEA (0.20mL, 1.12mmol) were dissolved in DMF and the microwave reaction was carried out at 120 ℃ and 20bar for 3 h. It was dissolved in EA, washed with 1N HCl saturated aqueous solution and then Na₂SO₄The EA layer was dried and filtered. The solvent was distilled off under reduced pressure, and MPLC (R) was passed through_f0.23, EA: hexane: 1:4) to afford compound 16b in 26.0% yield.

¹H NMR(400MHz,CDCl₃)d 7.28(s,1H),7.17(t,J＝9.2Hz,9.2Hz,4H),6.63(s,1H),4.67(s,2H),3.04(s,3H),2.35(s,3H).¹³C NMR(100MHz,CDCl₃)d 160.1,155.0,137.7,133.0,129.7,128.6,128.5,127.6,127.3,110.9,110.2,105.2,21.2.

Compounds 21a-21f were synthesized in the same manner as in reaction scheme 7 below.

[ reaction scheme 7]

19.2, 4-dihydroxy-5-isopropylbenzoic acid methyl ester (17)

Mixing compound 9(10.70g, 63.50mmol) and AlCl₃(16.90g, 127.0mmol) and 2-bromopropane (11.90mL, 127.0mmol) were dissolved in DCM (125mL) and refluxed at 50 ℃ for 24 hours under argon injection. 2 equivalents of AlCl are added in each case within 6 hours₃And 2-bromopropane. Adjusting the reaction mixture to pH 6 with a saturated 10% aqueous NaOH solution, removing the solvent by distillation under reduced pressure, and removing the residueThe residue was dissolved in EA and saturated NaHCO was used₃And (4) washing with an aqueous solution. Mixing EA layer with Na₂SO₄Dried, filtered and the solvent removed by distillation under reduced pressure. Purification by column chromatography using a mixed solvent of EA: hexane ═ 1:9 gave compound 17 in 34.5% yield.

¹H NMR(400MHz,CDCl₃)d 12.61(s,1H),7.52(s,1H),6.35(s,1H),6.31(s,1H),3.22-3.12(m,1H),2.61(s,3H),1.27(d,J＝6.8Hz,6H).¹³C NMR(100MHz,CDCl₃)d 170.7,161.6,159.6,128.1,127.1,105.7,103.2,52.2,26.7,22.8.

20.2, 4-dihydroxy-5-isopropylbenzoic acid (18)

Compound 17(4.60g, 21.90mmol) and LiOH (10g) were added H at 70 deg.C₂O (30mL) and MeOH (30mL) and refluxed for 12 hours. It was dissolved in EA and washed with 3N HCl saturated aqueous solution. Mixing EA layer with Na₂SO₄Drying, filtration and removal of the solvent by distillation under reduced pressure gave compound 18 in 60.5% yield.

¹H NMR(400MHz,CDCl₃)d 7.68(s,1H),6.30(s,1H),3.19-3.12(m,1H),1.17(d,J＝4.0Hz,6H).

21.4- ((5-chloro-2, 4-dihydroxy-N-methylbenzamido) methyl) benzoic acid methyl ester (19a) and 4- ((2, 4-dihydroxy-5-isopropyl-N-methylbenzamido) methyl) benzoic acid methyl ester (19b)

1 equivalent of compound 12 or 18, 1.5 equivalents of compound 8c, 1 equivalent of HOBt, 2 equivalents of EDC and 1 equivalent of DIPEA were dissolved in DMF and subjected to microwave reaction at 120 ℃ and 20bar for 3 hours. Dissolved in EA and treated with H₂After O-washing, the EA layer was washed with Na₂SO₄Dried and filtered, and then the solvent was removed by distillation under reduced pressure. Purification by MPLC according to the conditions of each compound gave compound 19a or 19b in yields of 76.1%, 81.7%, respectively.

19a:¹H NMR(500MHz,CDCl₃)d 8.03(d,J＝6.6Hz,2H),7.35(d,J＝6.6Hz,2H),7.25(s,1H),6.62(s,1H),4.75(s,2H),3.91(s,3H),3.07(s,3H).

19b:¹H NMR(500MHz,CDCl₃)d 8.05(d,J＝6.7Hz,2H),7.37(d,J＝6.7Hz,2H),7.11(s,1H),6.42(s,1H),4.76(s,2H),3.92(s,3H),3.13-3.04(m,1H),3.05(s,3H),0.94(d,J＝5.3Hz,6H).

22.4- ((5-chloro-2, 4-dihydroxy-N-methylbenzamido) methyl) benzoic acid (20a) and 4- ((2, 4-dihydroxy-5-isopropyl-N-methylbenzamido) methyl) benzoic acid (20b)

1 equivalent of Compound 19a or 19b and LiOH (2.0g) was added to H₂O (20mL) and MeOH (20mL) and stirred at room temperature for 3 hours. It was dissolved in EA and washed with 3N HCl saturated aqueous solution. Mixing EA layer with Na₂SO₄Drying and filtration, and removal of the solvent by distillation under reduced pressure gave compounds 20a and 20b in 84.8% and 88.1% yields, respectively.

20a:¹H NMR(500MHz,CDCl₃)d 8.13(d,J＝6.66Hz,2H),7.41(d,J＝6.6Hz,2H),7.30(s,1H),6.68(s,1H),4.79(s,2H),3.12(s,3H).

20b:¹H NMR(500MHz,MeOD)d 8.00(d,J＝6.5Hz,2H),7.41(d,J＝5.8Hz,2H),7.0(s,1H),6.34(s,1H),4.86(s,2H),3.18-3.11(m,1H),3.0(s,3H),1.11(d,J＝5.2Hz,6H).

23.5-chloro-2, 4-dihydroxy-N-methyl-N- (4- (methylcarbamoyl) benzyl) benzamide (21a)

Compound 20a (0.27g, 0.79mmol), 40% methylamine in distilled water (0.10mL, 1.18mmol), HOBt (0.11g, 0.79mmol), EDC (0.30g, 1.58mmol) and DIPEA (0.14mL, 0.79mmol) were dissolved in DMF and subjected to microwave reaction at 120 ℃ and 20bar for 2 hours. It was dissolved in EA, washed with 1N HCl saturated aqueous solution and Na₂SO₄Dried and filtered, and the solvent was removed by distillation under reduced pressure. Through MPLC (C18 column, R_f＝0.21，H₂O: MeOH ═ 4:1) purification afforded compound 21a in 16.7% yield.

¹H NMR(500MHz,CDCl₃)d 7.78(d,J＝6.6Hz,2H),7.36(d,J＝6.6Hz,2H),7.30(s,1H),6.68(s,1H),4.75(s,2H),3.09(s,3H),3.03(d,J＝3.8Hz,3H).

24.5-chloro-N- (4- (ethylcarbamoyl) benzyl) -2, 4-dihydroxy-N-methylbenzamide (21b)

The compound20a (0.27g, 0.79mmol), 70% ethylamine H₂O solution (0.10mL, 1.18mmol), HOBt (0.11g, 0.79mmol), EDC (0.30g, 1.58mmol), DIPEA (0.14mL, 0.79mmol) were dissolved in DMF and the microwave reaction was carried out at 120 ℃ and 20bar for 2 h. After dissolving in EA and washing with 1N HCl saturated aqueous solution, the EA layer was washed with Na₂SO₄Dried and filtered, and the solvent was removed by distillation under reduced pressure. Through MPLC (C18 column, R_f＝0.21，H₂O: MeOH ═ 4:1) purification afforded compound 21b in 31.2% yield.

¹H NMR(500MHz,CDCl₃)d 7.78(d,J＝6.6Hz,2H),7.35(d,J＝6.6Hz,2H),7.30(s,1H),6.67(s,1H),4.75(s,2H),3.54-3.49(m,2H),2.96(s,3H),1.26(t,J＝5.8Hz,5.8Hz,3H).¹³C NMR(100MHz,CDCl₃)d

25.5-chloro-2, 4-dihydroxy-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide (21c)

Compound 20a (0.26g, 0.76mmol), propylamine (0.10mL, 1.14mmol), HOBt (0.10g, 0.76mmol), EDC (0.30g, 1.52mmol) and DIPEA (0.10mL, 0.76mmol) were dissolved in DMF and the microwave reaction was carried out at 120 ℃ and 20bar for 3 hours. After dissolving in EA and washing with 1N HCl saturated aqueous solution, the EA layer was washed with Na₂SO₄Dried, filtered and the solvent removed by distillation under reduced pressure. Through MPLC (C18 column, R_f＝0.21，H₂O: MeOH ═ 7:3) purification afforded compound 21c in 45.5% yield.

¹H NMR(500MHz,CDCl₃)d 7.78(d,J＝6.6Hz,2H),7.35(d,J＝6.6Hz,2H),7.28(s,1H),6.67(s,1H),4.75(s,2H),3.46-3.42(m,2H),3.09(s,3H),1.67-1.62(m,2H),1.00(t,J＝5.9Hz,5.9Hz,H).

26.2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (methylcarbamoyl) benzyl) benzamide (21d)

Compound 20b (0.21g, 0.62mmol), 40% methylamine in distilled water (0.08mL, 0.93mmol), HOBt (0.08g, 0.62mmol), EDC (0.23g, 1.24mmol) and DIPEA (0.11mL, 0.62mmol) were dissolved in DMF and subjected to microwave reaction at 120 ℃ and 20bar for 3 hours. It was dissolved in EA, washed with 1N HCl saturated aqueous solution and Na₂SO₄Dried and filtered, and the solvent was removed by distillation under reduced pressure. Through MPLC (C18 column, R_f＝0.21，H₂O: MeOH ═ 7:3) purification afforded compound 21d in 36.1% yield.

¹H NMR(500MHz,CDCl₃)d 7.79(d,J＝6.5Hz,2H),7.36(d,J＝6.4Hz,2H),7.08(s,1H),6.41(s,1H),6.46(s,2H),3.08(s,3H),3.06-3.03(m,1H),0.98(d,J＝5.3Hz,6H).

N- (4- (ethylcarbamoyl) benzyl) -2, 4-dihydroxy-5-isopropyl-N-methylbenzamide (21e)

Compound 20b (0.22g, 0.64mmol), 70% aqueous ethylamine distilled solution (0.08mL, 0.97mmol), HOBt (0.09g, 0.64mmol), EDC (0.25g, 1.29mmol) and DIPEA (0.12mL, 0.64mmol) were dissolved in DMF and subjected to microwave reaction at 120 ℃ and 20bar for 3 hours. It was dissolved in EA, washed with 1N HCl saturated aqueous solution and Na₂SO₄Dried and filtered, and the solvent was removed by distillation under reduced pressure. Through MPLC (C18 column, R_f＝0.21，H₂O: MeOH ═ 7:3) to obtain compound 21e in 24.3% yield.

¹H NMR(500MHz,CDCl₃)d 7.78(d,J＝6.6Hz,2H),7.33(d,J＝6.6Hz,2H),7.05(s,1H),6.43(s,1H),4.73(s,2H),3.52-3.47(m,2H),3.07-3.05(m,1H),3.05(s,3H),1.27-1.23(m,3H),0.98(d,J＝5.4Hz,6H).

28.2, 4-dihydroxy-5-isopropyl-N-methyl-N- (4- (propylcarbamoyl) benzyl) benzamide (21f)

Compound 20b (0.22g, 0.64mmol), propylamine (0.08mL, 0.96mmol), HOBt (0.09g, 0.64mmol), EDC (0.25g, 1.28mmol), DIPEA (0.11mL, 0.64mmol) were dissolved in DMF and the microwave reaction was carried out at 120 ℃ and 20bar for 3 hours. It was dissolved in EA, washed with 1N HCl saturated aqueous solution and Na₂SO₄Dried and filtered, and then the solvent was removed by distillation under reduced pressure. Through MPLC (C18 column, R_f＝0.21，H₂O: MeOH ═ 7:3) purification afforded compound 21f in 22.3% yield.

¹H NMR(500MHz,CDCl₃)d 7.76(d,J＝6.6Hz,2H),7.29(d,J＝6.6Hz,2H),7.02(s,1H),6.43(s,1H),4.70(s,2H),3.41-3.37(m,2H),3.07-3.05(m,1H),3.02(s,3H),1.63(s,2H),0.97-0.92(m,9H).

N-benzyl-2, 4-dihydroxy-5-isopropyl-N-methylbenzamide (21g)

2, 4-dihydroxy-5-isopropylbenzoic acid (0.33g, 1.70mmol), N-methylaniline (0.33g, 2.54mmol), EDC (0.65g, 3.30mmol) and DIPEA (0.30mL, 1.70mmol) were dissolved in DMF and the microwave reaction was carried out at 120 ℃ and 20bar for 3 hours. It was dissolved in EA, washed with 1N HCl saturated aqueous solution and Na₂SO₄Dried and filtered, and then the solvent was removed by distillation under reduced pressure. Using EA hexane ═ 1:4 (R)_f0.18) was purified to obtain 21g of the compound with a yield of 15.5%.

¹H NMR(500MHz,CDCl₃)δ10.5(s,1H),7.42-7.39(m,2H),7.34-7.29(m,3H),6.38(s,1H),5.34(s,1H),4.74(s,2H),3.09(s,3H),3.06-2.95(m,1H),0.96(d,J＝5.4Hz,6H).

< example 4> evaluation of biological Activity of benzamide Compound

1. Evaluation of binding Capacity to HSP90

Fluorescence polarization assays were performed to confirm the ability of the synthesized compounds to bind HSP90 with concentration. 1M Dithiothreitol (DTT)10mg/M BGG (bovine gamma globulin) was added to Hexafluorobenzene (HFB) buffer (20mM HEPES pH 7.3, 50mM KCl, 5mM MgCl)₂20mM Na₂MoO₄0.01% NP4O, triple distilled water) and mixed. Then, 100nM Gambogic Acid (GA) -FITC (fluorescein isothiocyanate) was added and reacted at room temperature for 10 minutes. Each 100 μ L of the mixture was dispensed into a control well of a 96-well plate, 2 μ L HSP90 α was added to the remaining mixtures, and each 100 μ L was dispensed into the other wells. 98. mu.L each was dispensed into wells of the compound to be treated, and 2. mu.L each was added at each concentration of 5mM, 2.5mM, 500. mu.M, 50. mu.M, 25. mu.M, 5. mu.M, 500nM or 50 nM. After 1, 4, 6 or 18 hours of reaction, the fluorescence polarization was measured by a microplate reader at 495/530 nm. The binding capacity of compounds to HSP90 is expressed as mP (milli-polarized units 1000mP units). The results are shown in table 3 below.

2. Measurement of cell viability

To confirm the change in cell viability with the concentration of the compound synthesized in gefitinib-resistant H1975 cells (ATCC), MTS [3- (4, 5-dimethylthiazol-2-yl) -5- (3-methylpiperidin-3-yl) -carboxymethoxyphenyl) -2- (4-sulfophenyl) -2H-tetrazolium salt, inner salt, was performed]And (6) analyzing. When the cells were cultured to occupy 80% of the bottom of the culture dish, the cells were separated and diluted to 1.5X 10 with RPMI 1640 medium³Concentration of cells/well. 100 μ L each of the suspensions was added to each well of a 96-well plate and cultured for 14 hours. Then, the medium was replaced with a culture solution (1 a-g: 0, 1. mu.M, 5. mu.M, 10. mu.M, 30. mu.M, 50. mu.M or 100. mu.M; 14a-I, 16a, b, 21 a-f: 0, 0.01. mu.M, 0.1. mu.M, 1. mu.M, 5. mu.M, 10. mu.M, 30. mu.M, 50. mu.M, 70. mu.M or 100. mu.M) treated with each concentration of the compound, and the culture was carried out for 3 days. Each 20. mu.L of MTS solution was dispensed into each well and provided with 5% CO at 37 deg.C₂The reaction was carried out in the incubator for 1 hour. Absorbance was measured at 490/690nm for 1 hour using a microplate reader, and cell viability was calculated from the concentration in percent (%) and IC₅₀And (mu M) meter. The results are shown in table 3 below.

[ chemical formula 2]

[ Table 3]

The results of measurement of binding ability between the benzamide compounds 14a to 14i, 16a, 16b and 21a to 21f of the present invention and HSP90 shown in Table 3It was shown that the remaining compounds, except 14a and 14f, have high binding capacity at the nanomolar level of concentration. Among these, compound 21f showed the best binding capacity, IC₅₀Was 5.3 nM.

Furthermore, the results of measurement of cell viability of the compounds measured in H1975 cells shown in table 3 confirm that all benzamide compounds inhibit cell proliferation in a time-dependent manner. In particular, compound 21f showed good efficacy, EC₅₀Was 420 nM.

3. Protein expression analysis

Compound 21f with good efficacy was selected and the proliferative effect of HSP90 client proteins in the same cell line was confirmed, wherein the HSP90 client proteins Her2 (human EGFR related 2), EGFR (epidermal growth factor receptor), Met and c-Raf were used.

Gefitinib resistant H1975 cells were cultured in medium supplemented with 10% Fetal Bovine Serum (FBS) for 24 hours, and the cells were isolated, harvested and diluted to 5X 10 with RPMI 1640 medium⁵Cells/well. 5mL each of the suspensions was added to a 6mm petri dish and incubated for 24 hours. Then, the medium was replaced with a culture solution treated with each concentration of the compound (21 f: 0, 0.05. mu.M, 0.1. mu.M, 0.5. mu.M or 1. mu.M; GA: 1. mu.M), and cultured for 24 hours. After incubation, cells were harvested and centrifuged at 1300rpm for 5 minutes at 4 ℃ to remove the supernatant. The precipitate was washed with phosphate buffered saline and centrifuged again under the same conditions to remove the supernatant. Lysis buffer was added to the remaining pellet and vortexed at 5 minute intervals for 30 minutes. The supernatant was separated by centrifugation at 16000rcf for 4 minutes at 4 ℃ and the protein was quantified using the BCA (bovine serum albumin) kit. SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) was performed using 10, 12% run gels and 4% stacking gels (10 mA/gel). The isolated proteins were transferred to immunoblotting PVDF membrane (polyvinylidene fluoride membrane) at 100V for 75 minutes. The membrane was blocked with a 5% skim milk solution for 2 hours, and then primary antibody diluted at 1: 750-. After three washes with TBS-T (Tris buffered saline and Tween 20), ECL (enhanced chemistry) was usedLuminescence) solution was detected with an image analyzer.

The results shown in fig. 5 confirm that the proliferation of HSP90 client protein is inhibited in a concentration-dependent manner by treatment with compound 21 f. For Her2, Met and Akt, expression was significantly reduced at 0.5. mu.M; for EGFR, expression was significantly reduced at 0.1. mu.M. In addition, the expression of HSP70 was also increased at 0.5. mu.M.

While the invention has been described in connection with what is presently considered to be practical exemplary embodiments, it is to be understood that the invention is not to be limited to the disclosed embodiments, but on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.